CN117800976A - Nitrogen-containing heterocyclic compound, preparation method and application - Google Patents
Nitrogen-containing heterocyclic compound, preparation method and application Download PDFInfo
- Publication number
- CN117800976A CN117800976A CN202311267818.5A CN202311267818A CN117800976A CN 117800976 A CN117800976 A CN 117800976A CN 202311267818 A CN202311267818 A CN 202311267818A CN 117800976 A CN117800976 A CN 117800976A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- membered
- heterocycloalkyl
- group
- alternatively
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Nitrogen-containing heterocyclic compound Chemical class 0.000 title claims abstract description 183
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- 239000000651 prodrug Substances 0.000 claims abstract description 43
- 229940002612 prodrug Drugs 0.000 claims abstract description 43
- 239000012453 solvate Substances 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims description 200
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 62
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 58
- 125000005842 heteroatom Chemical group 0.000 claims description 52
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 229920006395 saturated elastomer Polymers 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 20
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052698 phosphorus Inorganic materials 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 102000016914 ras Proteins Human genes 0.000 claims description 15
- 150000001721 carbon Chemical group 0.000 claims description 14
- 102200006539 rs121913529 Human genes 0.000 claims description 14
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
- 125000003003 spiro group Chemical group 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 9
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 102000008300 Mutant Proteins Human genes 0.000 claims description 8
- 108010021466 Mutant Proteins Proteins 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052721 tungsten Inorganic materials 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 206010016629 fibroma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical group C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 168
- 239000000543 intermediate Substances 0.000 description 151
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 113
- 239000000243 solution Substances 0.000 description 113
- 238000006243 chemical reaction Methods 0.000 description 110
- 239000007787 solid Substances 0.000 description 83
- 239000011541 reaction mixture Substances 0.000 description 68
- 230000002829 reductive effect Effects 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 235000002639 sodium chloride Nutrition 0.000 description 54
- 239000012043 crude product Substances 0.000 description 53
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000003208 petroleum Substances 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- 239000003480 eluent Substances 0.000 description 32
- 239000000203 mixture Substances 0.000 description 32
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 30
- 238000010898 silica gel chromatography Methods 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 238000001514 detection method Methods 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 238000001819 mass spectrum Methods 0.000 description 13
- 230000005311 nuclear magnetism Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 108010014186 ras Proteins Proteins 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 239000011593 sulfur Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 150000007529 inorganic bases Chemical class 0.000 description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229910052723 transition metal Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101150105104 Kras gene Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000002619 bicyclic group Chemical group 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 150000003624 transition metals Chemical class 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000013067 intermediate product Substances 0.000 description 8
- 150000007530 organic bases Chemical class 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- 238000012054 celltiter-glo Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 206010069755 K-ras gene mutation Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 102200006538 rs121913530 Human genes 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000005414 inactive ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- 235000003270 potassium fluoride Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003277 amino group Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HRADVHZVMOMEPU-UHFFFAOYSA-N 3-iodopyrrolidine-2,5-dione Chemical compound IC1CC(=O)NC1=O HRADVHZVMOMEPU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- SCLFRABIDYGTAZ-UHFFFAOYSA-N methylphosphonic acid dichloride Chemical compound CP(Cl)(Cl)=O SCLFRABIDYGTAZ-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004822 1,1-dimethylpropylene group Chemical group [H]C([H])([H])C([*:1])(C([H])([H])[H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 1
- 125000005938 2,3-dihydro-1H-isoindolyl group Chemical group 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 description 1
- WAEZOSSWRXDWAX-UHFFFAOYSA-N 2,6-dichloropyridin-4-amine Chemical compound NC1=CC(Cl)=NC(Cl)=C1 WAEZOSSWRXDWAX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- YRYQLVCTQFBRLD-UIOOFZCWSA-N 2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1[C@H](CN(CC1)C=1C2=C(N=C(N=1)OC[C@H]1N(CCC1)C)CN(CC2)C1=CC=CC2=CC=CC(=C12)C)CC#N YRYQLVCTQFBRLD-UIOOFZCWSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- VMZKZXMOHWFESX-UHFFFAOYSA-N 2-amino-4-bromo-3,6-difluorobenzoic acid Chemical compound Nc1c(F)c(Br)cc(F)c1C(O)=O VMZKZXMOHWFESX-UHFFFAOYSA-N 0.000 description 1
- HDKYIPMDJJVHHA-UHFFFAOYSA-N 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid Chemical compound Nc1c(F)c(Br)c(Cl)cc1C(O)=O HDKYIPMDJJVHHA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MZPLLPUWIXCTEI-UHFFFAOYSA-N 7-bromo-2,4,6-trichloro-8-fluoroquinazoline Chemical compound Fc1c(Br)c(Cl)cc2c(Cl)nc(Cl)nc12 MZPLLPUWIXCTEI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150117869 Hras gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 229940124785 KRAS inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150073096 NRAS gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- RIJGJCBKSVIKAE-UHFFFAOYSA-N O=C(C1=C(C(Cl)=C2Br)F)NC(Cl)=NC1=C2F Chemical compound O=C(C1=C(C(Cl)=C2Br)F)NC(Cl)=NC1=C2F RIJGJCBKSVIKAE-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- ORLQHILJRHBSAY-UHFFFAOYSA-N [1-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1(CO)CCCCC1 ORLQHILJRHBSAY-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005571 adamantylene group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- NYUVWFKXXNINGH-UHFFFAOYSA-N benzyl thiomorpholine-4-carboxylate Chemical compound C1CSCCN1C(=O)OCC1=CC=CC=C1 NYUVWFKXXNINGH-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- JIDMEYQIXXJQCC-UHFFFAOYSA-L copper;2,2,2-trifluoroacetate Chemical compound [Cu+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F JIDMEYQIXXJQCC-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- UWZOQSHXFQWDEJ-UHFFFAOYSA-N dichlorophosphorylcyclopropane Chemical compound ClP(Cl)(=O)C1CC1 UWZOQSHXFQWDEJ-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- VLODBNNWEWTQJX-UHFFFAOYSA-N iodocyclopropane Chemical group IC1CC1 VLODBNNWEWTQJX-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WQWUQDVFRYMMCY-UHFFFAOYSA-N naphthalen-1-yl trifluoromethanesulfonate Chemical compound C1=CC=C2C(OS(=O)(=O)C(F)(F)F)=CC=CC2=C1 WQWUQDVFRYMMCY-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OEQJOYQHIGIVTN-UHFFFAOYSA-N tert-butyl nonanoate Chemical compound CCCCCCCCC(=O)OC(C)(C)C OEQJOYQHIGIVTN-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- NJZPXYDIPUBVIY-UHFFFAOYSA-K trifluoropalladium Chemical compound F[Pd](F)F NJZPXYDIPUBVIY-UHFFFAOYSA-K 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The invention discloses a nitrogen-containing heterocyclic compound, a preparation method and application thereof, in particular to a nitrogen-containing heterocyclic compound shown in a general formula (I), or pharmaceutically acceptable salt thereof, or enantiomer, diastereoisomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, a preparation method thereof and application thereof in pharmacy, wherein the definition of each group is as described in the specification.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and in particular relates to a nitrogen-containing heterocyclic compound, a compound for inhibiting activity of Ras mutein, a preparation method and application thereof.
Background
Ras is the first oncogene identified in human tumors, and was first discovered in two murine sarcoma viruses. Ras gene familyThere are three members, HRas, KRas, NRas respectively. In human tumors, KRas mutations are most common, accounting for about 85%. Previous studies have shown that KRas mutations are oncogenic because of missense mutations at codon 12, altering the structure of the KRas protein and allowing it to remain active. Ras plays a major role in signaling pathway in activating kinases that control gene transcription, thereby regulating cell differentiation and proliferation, and is intimately involved in tumor cell survival, proliferation, migration, metastasis, and angiogenesis. It is counted that a high proportion of KRas mutations occur in malignant tumors such as pancreatic cancer, colorectal cancer, ovarian cancer, cholangiocarcinoma and the like. However, targeting drugs for common proto-oncogenes such as EGFR, BCL, etc. have been developed for several generations since the first discovery of KRas oncogenes, but targeting drugs for KRas have not been successfully developed all the time. Targeting drugs against KRas pathway mutant tumors have been mainly focused on farnesyl transferase inhibitors and Raf-MEK pathway inhibitors, but have had little effect. In recent years, inhibitors against KRAS-specific gene mutations have been developed as hot spots, although some inhibitors have gradually moved from preclinical hatching to clinical studies, such as KRAS G12C AMG510, MRTX1257, etc., and shows a certain efficacy in early clinical trials. Global first money KRAS G12C The first clinical data of the inhibitor AMG510 was formally published by the american clinical oncology institute held at month 6 of 2019, in which the drug AMG510 was installed to be shown to prevent tumor growth in most patients with non-small cell lung and colorectal cancer with KRas mutations.
However, the current KRas inhibitors are also limited to only KRas G12C Patients with mutations and a large number of KRAS G12C Other than mutation inhibitor drug development has not been broken through, such as highly-developed KRas G12D 、KRas G12V 、KRas G13D And the like. Thus, highly specific and excellent drug-specific KRAS-directed drugs were found and sought G12C Targeted drugs of specific mutant genes other than those have become a great hotspot in the industry. Through the long-term efforts of the inventor, a class of KRAS mutation inhibitors with novel structure and action mechanism, especially KRAS, is discovered G12D The mutation has better activity and drug-forming property.
Disclosure of Invention
The invention aims to solve the technical problems of KRAS in the prior art G12D The problem of lack of inhibitors provides a class of nitrogen-containing heterocyclic compounds, a preparation method and application. The nitrogen-containing heterocyclic compounds provided by the invention are brand new KRAS G12D Inhibitors, which exhibit good inhibitory activity; the preparation has good inhibitory activity on tumor cells and good drug-forming property, and has wide drug development prospect.
The invention solves the technical problems by the following technical proposal:
the invention provides a nitrogen-containing heterocyclic compound shown in a general formula (I), or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof,
wherein,
R 1 selected from substituted or unsubstituted 3-12 membered cycloalkyl or heterocycloalkyl, said substituents being selected from one or more R 10 ,R 10 Independently selected from: halogen, cyano, hydroxy, amino, acyl, sulfonyl, - (CO) -NR 11 R 12 、C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Alkenyl, C 1 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylcyano, C 1 -C 6 Alkyl hydroxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered aryl or heteroaryl, or two R 10 And together with the carbon atom or heteroatom to which they are attached form a 3-12 membered saturated or partially unsaturated or aromatic carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings; r is R 11 、R 12 Independently selected from hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, 3-8 membered cycloalkyl or heterocycloalkyl, or R 11 、R 12 Together with the attached N atom form a 3-8 membered cycloalkyl or heterocycloalkyl group; the heterocyclic alkyl, heteroaryl and heterocyclic ring system contains 1-3 hetero atoms selected from N, O, S, P, si, se;
R 2 selected from substituted or unsubstituted C 1 -C 6 Alkyl, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-12 membered aryl or heteroaryl, C 1 -C 6 An alkyl-substituted 3-12 membered cycloalkyl or heterocycloalkyl, a 5-16 membered saturated or partially unsaturated carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings; the substituents are one or more R 21 ,R 21 Independently selected from the following groups: halogen, cyano, hydroxy, amino, (C) 1 -C 6 Alkyl) NH- (C 1 -C 6 Alkyl group 2 N-、(C 1 -C 6 Alkyl) NH-C 1 -C 6 Alkyl-, (C) 1 -C 6 Alkyl group 2 N-C 1 -C 6 Alkyl-, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-12 membered aryl or heteroaryl, 3-12 membered cycloalkyl or heterocycloalkyl substituted C 1 -C 6 Alkyl, etc., or two R 21 Together with the carbon atom or heteroatom to which they are attached, form a 3-8 membered cycloalkyl or heterocycloalkyl group; the 3-12 membered heterocycloalkyl, 5-12 membered heteroaryl, 3-12 membered heterocycloalkyl substituted C 1 -C 6 The heterocycloalkyl group, the 5-16 membered saturated or partially unsaturated heterocyclic ring system or the 5-12 membered heteroaryl group in the alkyl group contains 1 to 3N, O, S, P, si, B, se heteroatoms, which may optionally be in different oxidation states; r is R 21 May further optionally be substituted with one or more R 211 Substituted, R 211 Independently selected from halogen, cyano, hydroxy, amino, C 1 -C 6 Alkyl-imino-, cyano-imino-, 3-6 membered cycloalkyl-imino-, C 1 -C 6 Alkyl or haloalkyl, C 1 -C 6 Alkoxy, 3-to 10-membered cycloalkyl or heterocycloalkyl, 3-to 10-membered halocycloalkyl or haloheterocycloalkyl substitution; r is R 211 Wherein said heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O, S, P, si, se;
l is selected from carbon-carbon single bond, carbon-carbon double bond, carbon-carbon triple bond, CHR 5 、O、S(O) t 、NR 5a R 5b ;R 5 、R 5a And R is 5b Selected from H, C 1 -C 6 Alkyl of (a);
L 1 selected from direct bond, CHR 5 、O、S(O) t 、NR 5a R 5b ;R 5 、R 5a And R is 5b Selected from H, C 1 -C 6 Alkyl of (a);
R 4 a group selected from one or more of the following groups: hydrogen, deuterium, halogen, hydroxy, amino, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, 3-to 12-membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, -P (O) t- (C) 1 -C 6 Alkyl), -S (O) t- (C) 1 -C 6 Alkyl), an amide group, a sulfonamide group, a urea group, a 5-to 12-membered aryl or heteroaryl group, or R as defined above 1 And R is 4 Any two substituents between the two groups form a 3-12 membered saturated or partially unsaturated or aromatic ring system or aromatic heterocyclic system through carbon atoms or hetero atoms; the heterocycloalkyl, heteroaryl and aromatic heterocyclic system contains 1-3 hetero atoms selected from N, O, S, P;
t is selected from 0-2;
alternatively, R 1 And R is 4 And the carbon or heteroatom (nitrogen, or oxygen, or sulfur) to which they are attached form a new saturated or unsaturated heterocyclic ring system, said new saturated or unsaturated heterocyclic ring system being a 6-7 membered heterocyclic ring;
ar is selected from a substituted or unsubstituted 5-12 membered aromatic or heteroaromatic ring, and may be substituted with one or more R 3 Substitution; r is R 3 Independently selected from halogen, hydroxy, amino, cyanoRadical, C 1 -C 6 Alkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, (C) 1 -C 6 Alkyl) NH- (C 1 -C 6 Alkyl group 2 N-; the heterocycloalkyl group and the aromatic heterocycle contain 1 to 3 hetero atoms selected from N, O, S, P;
m is N or CR 6 ;R 6 Selected from hydrogen, deuterium, halogen, -CN, C 1 -C 3 Alkyl, C 1 -C 3 A haloalkyl group;
cy is selected from a 5-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring system, or a 5-6 membered aromatic or heteroaromatic ring system; the heterocyclic ring system or the aromatic heterocyclic ring system contains 1-3 hetero atoms selected from N, O, S, P, B, si.
In certain preferred embodiments of the present invention, certain groups of the nitrogen-containing heterocyclic compounds of formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereomers, tautomers, torsional isomers, solvates, polymorphs, or prodrugs thereof, are defined as follows, and the non-mentioned groups are as described in any one of the embodiments of the present invention (abbreviated as "in certain embodiments of the present invention").
In certain embodiments of the present invention, the nitrogen-containing heterocyclic compound of formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, wherein,
when R is 2 Selected from 3-12 membered heterocycloalkyl, 5-12 membered heteroaryl, C 1 -C 6 An alkyl-substituted 3-12 membered heterocycloalkyl, 5-16 membered saturated or partially unsaturated heterocyclic ring system including spiro, bridged, fused or fused rings; the heterocycloalkyl, heteroaryl, and heterocyclic ring systems contain 1 to 3 heteroatoms independently selected from N, O, P, S, si, se;
alternatively, when R 21 Independently selected from 3-12 membered heterocycloalkyl, 5-12 membered heteroaryl, 3-12 membered heterocycloalkyl substituted C 1 -C 6 Alkyl, etc., orTwo R 21 When taken together with the carbon atom or heteroatom to which they are attached form a 3-8 membered heterocycloalkyl; the heterocycloalkyl group and heteroaryl group contain 1-3N, O, S, P, si, B, se heteroatoms, and the heteroatoms can be optionally in different oxidation states.
In certain embodiments of the invention, a nitrogen-containing heterocyclic compound of formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, has a structure as shown in formula (II):
wherein W, W 1 Each independently selected from N or CR 4 ,Ar、R 3 、R 4 、M、L、L 1 、R 10 、R 2 、R 1 The scope of (2) is as described elsewhere herein.
In certain aspects of the invention, C 2 -C 6 Alkenyl group is C 2 -C 4 Alkenyl, preferably ethenyl or propenyl;
in certain aspects of the invention, C 2 -C 6 Alkynyl is C 2 -C 4 Alkynyl, preferably
In certain aspects of the invention, C 1 -C 6 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, primary butyl, secondary butyl or tertiary butyl;
in certain aspects of the invention, C 1 -C 6 Halogen in the haloalkyl is fluorine, chlorine, bromine or iodine;
in certain embodiments of the invention, the 3-6 membered cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexenyl, or cyclohexyl.
In certain aspects of the invention, R 10 、R 21 、R 211 The number of (2) is 0,1. 2 or 3.
In certain embodiments of the present invention, the nitrogen-containing heterocyclic compound of formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, wherein,
m is N, C-H, C-F, C-CN;
alternatively, cy is selected from the group consisting of:
alternatively, R 4 Preferably selected from hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl groups of (a) and the like;
alternatively, R 1 Selected from a substituted or unsubstituted 5-10 membered cycloalkyl or heterocycloalkyl, preferably from a substituted or unsubstituted piperidine ring, piperazine ring, homopiperazine ring, pyrrolidine ring, homopiperidine ring, morpholine ring, homomorpholine ring, said substituents R 10 Preferably from halogen, C1-C6 alkyl, hydroxy, amino, =O, 3-to 6-membered saturated or partially unsaturated carbocyclic or heterocyclic ring systems, or form a substituted or unsubstituted bicyclic ring system with 5-to 6-membered aryl or heteroaryl, or two R 10 And together with the carbon atom or heteroatom to which they are attached form a 5-6 membered saturated or partially unsaturated or aromatic carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings;
Alternatively, ar is preferably selected from a benzene ring, a pyridine ring, a naphthalene ring, a benzothiazole ring, a benzothiophene ring, an indazole ring, an indole ring, an azaindole ring, a benzimidazole ring, etc.;
alternatively, R 3 Independently selected from hydrogen, halogen, hydroxy, amino, cyano, and C 1 -C 6 Alkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy groups, and the like;
alternatively, L is selected from: CH (CH) 2 O, NH or S;
alternatively, L 1 Selected from: direct bond, CH 2 O, NH or S;
alternatively, R 2 Selected from the group consisting ofWherein m and n are each an integer from 0 to 3; preferably 1 or 2; ry is selected from 3-12 membered cycloalkyl or heterocycloalkyl, 5-10 membered aryl, 5-10 membered heteroaryl, said heterocycloalkyl or heteroaryl containing 1-3N, O, S, P, si, B, se heteroatoms, which optionally may be in different oxidation states; r is R p And R is q Selected from hydrogen, halogen, C 1 -C 6 Alkyl or alkoxy, 3-6 membered cycloalkyl or heterocycloalkyl, hydroxy, amino, or R p And R is q Forming a 3-8 membered cycloalkyl or heterocycloalkyl; r is R p 、R q Ry may optionally be further substituted with one or more R 211 Substituted, halogen, cyano, C 1 -C 6 Alkyl-imino-, cyano-imino-, 3-6 membered cycloalkyl-imino-, C 1 -C 6 Alkyl or haloalkyl, 3-12 membered cycloalkyl or heterocycloalkyl, 3-12 membered halocycloalkyl or haloheterocycloalkyl.
In certain embodiments of the present invention, the nitrogen-containing heterocyclic compound of formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, is characterized in that R 1 Preferably selected from
Alternatively, cy is selected from
Alternatively, R 3 Ar is selected from a substituted or unsubstituted benzene ring, pyridine ring, naphthalene ring, benzothiazole ring, benzothiophene ring; the substituents are independently selected from hydroxy, amino, halogen, cyano, vinyl, ethynyl, C1-C3 alkyl or haloalkyl;
alternatively, L is preferably selected from-O-;
alternatively, L 1 Preferably from direct bond, CH 2 ;
Alternatively, R 2 Preferably selected fromWherein Ry is selected from substituted 5-12 membered cycloalkyl or 5-12 membered heterocycloalkyl containing 1-3S, or P, or Si, or selenium; r is R p And R is q Selected from hydrogen, halogen, C 1 -C 6 Alkyl or alkoxy, hydroxy, amino, or R p And R is q Forming a 3-8 membered cycloalkyl or heterocycloalkyl;
alternatively, R 4 Selected from hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl groups of (a) and the like;
in some embodiments of the present invention, the nitrogen-containing heterocyclic compound represented by formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, wherein,
M is preferably N, C-H, C-F, C-CN;
alternatively, cy is preferably selected from
Alternatively, R 1 Preferably selected from:
r is as described above 1 Any hydrogen of the radicals being able to be replaced by halogen, hydroxy, C 1 -C 6 Alkyl, or = O substitution;
alternatively, R 3 Ar is selected from
Alternatively, L is selected from O;
alternatively, L 1 Selected from direct bond, CH 2 ;
Alternatively, R 2 Preferably is R 6 Selected from hydrogen, deuterium, halogen, cyano, C 1 -C 3 Alkyl or C 1 -C 3 A haloalkyl group;
alternatively, R 4 Selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, trifluoromethyl, cyano, amino, cyclopropyl, vinyl, ethynyl, and the like.
In certain aspects of the invention, when R 1 And R is 4 The compounds of formula (I) may have the structure of formula (III) when a new heterocyclic ring system is constituted by sharing one carbon or heteroatom (nitrogen, or oxygen, or sulfur atom),
wherein r is 0, 1 or 2; p is selected from 1 or 2; w, W 1 Independently selected from N or CR 4 ;
L 2 Is O, S or NR 7 ,R 7 Is hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl; l (L) 2 Preferably O;
q is- (CH) 2 ) q -L 3 -(CH 2 ) q -or not present; q is selected from 1 or 2;
L 3 selected from chemical bonds, O, S, NR 8 Or is absent, R 8 Is hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl; q is preferably selected from-CH 2 CH 2 -;
R 10 Independently selected from deuterium, halogen, cyano, hydroxy, amino, C1-C6 acyl, sulfonyl, - (CO) -NR 11 R 12 、C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylcyano, C 1 -C 6 Alkyl hydroxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered aryl or heteroaryl; other groups Ar, R 3 、R 4 、M、L、L 1 、R 2 、R 10 As described elsewhere herein;
in some aspects of the present invention,preferably +.>
In certain embodiments of the present invention, the 3-12 membered cycloalkyl or heterocycloalkyl substituted alkyl is preferably (3-12 membered cycloalkyl or heterocycloalkyl) -C 1 -C 6 Alkyl-; the alkyl-substituted amino group is preferably (C) 1 -C 6 Alkyl) NH-or (C) 1 -C 6 Alkyl) (C) 1 -C 6 Alkyl) N-;
in certain aspects of the invention, R 11 、R 12 Independently selected from hydrogen, halogen, methyl;
in certain aspects of the invention, when R 11 、R 12 When taken together with the attached N atom form a 5-8 membered heterocycloalkyl, the 3-8 membered heterocycloalkyl is preferably
In certain aspects of the invention, R p And R is R q Forming a three-membered carbocyclic ring with the attached carbon atom;
in certain aspects of the invention, when R 21 In the case of 3-12 membered heterocycloalkyl, the 3-12 membered heterocycloalkyl is 5-10 membered heterocycloalkyl, preferably
In certain aspects of the invention, two R 21 When taken together with the carbon atom or heteroatom to which they are attached, form a 3-8 membered cycloalkyl, the 3-8 membered cycloalkyl is a three membered carbocyclic ring;
in certain embodiments of the invention, ry is preferably
In certain aspects of the invention, when R 10 Is C 1 -C 6 When alkyl hydroxy of (C) 1 -C 6 Preferably HO-CH 2 -、HO-CH 2 -CH 2 -;
In certain embodiments of the invention, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, has the following structure:
thus, throughout this specification, one skilled in the art may select the groups and substituents thereof in the nitrogen-containing heterocyclic compound of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, to provide a stable nitrogen-containing heterocyclic compound of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof, including but not limited to the compounds described in the examples of the invention.
The nitrogen-containing heterocyclic compounds of formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereomers, tautomers, torsional isomers, solvates, polymorphs, or prodrugs thereof, according to the invention, may be synthesized by methods that include methods similar to those known in the chemical arts, the steps and conditions of which may be referred to in the art as procedures and conditions of similar reactions, particularly in light of the description herein. The starting materials are typically from commercial sources, such as Aldrich or can be readily prepared using methods well known to those skilled in the art (available via SciFinder, reaxys on-line databases).
In the invention, the nitrogen-containing heterocyclic compound shown in the formula I or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof can also be prepared into the nitrogen-containing heterocyclic compound shown in the formula I or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, and other nitrogen-containing heterocyclic compounds shown in the formula I or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof can be obtained by peripheral modification by adopting a conventional method in the art.
In general, the compounds of the invention may be prepared by the methods described herein, wherein the substituents are as defined in formula I, unless otherwise indicated. The following reaction schemes and examples are provided to further illustrate the present invention.
The invention also provides a preparation method of the nitrogen-containing heterocyclic biaryl compound shown in the formula I, which comprises the following steps:
a) Combining a compound of formula (A) with R 1 -H under alkaline conditions, to produce a compound of formula (B);
b) Combining a compound of formula (B) with R 2 -L-H is subjected to substitution reaction or metal catalytic coupling reaction under alkaline condition to generate a compound of the general formula (C);
c) The compound of the general formula (C) and arylboric acid or arylborate or arylmetal reagent (Ar-M) are subjected to a transition metal catalytic coupling reaction to generate the general formula (I).
X is halogen, and the definition of each other group is as described above;
preferably, each of said steps a), b), c) is performed in a solvent, and said solvent is selected from the group consisting of: water, methanol, ethanol, isopropanol, butanol, ethylene glycol methyl ether, N-methylpyrrolidone, dimethyl sulfoxide, tetrahydrofuran, toluene, methylene chloride, 1, 2-dichloroethane, acetonitrile, N-dimethylformamide, N-dimethylacetamide, dioxane, or a combination thereof.
Preferably, the inorganic base is selected from the group consisting of: sodium hydride, potassium hydroxide, sodium acetate, potassium t-butoxide, sodium t-butoxide, potassium fluoride, cesium fluoride, potassium phosphate, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, or a combination thereof; the organic base is selected from the group consisting of: pyridine, triethylamine, N, N-diisopropylethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), lithium hexamethyldisilazide, sodium hexamethyldisilazide, lutidine, or combinations thereof.
Preferably, the transition metal catalyst is selected from the group consisting of: tris (dibenzylideneacetone) dipalladium (Pd) 2 (dba) 3 ) Tetrakis (triphenylphosphine) palladium (Pd (PPh) 3 ) 4 ) Palladium acetate, palladium chloride, dichloro-bis (triphenylphosphine) palladium, trifluoropalladium acetate, triphenylphosphine palladium acetate, [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride, bis (triphenylphosphine) palladium dichloride, 1, 2-bis (diphenylphosphino) ethane palladium dichloride, or a combination thereof; the catalyst ligand is selected from the group consisting of: tri-tert-butylphosphine, tri-tert-butylphosphine tetrafluoroborate, tri-n-butylphosphine, triphenylphosphine, tri-p-benzylphosphine, tricyclohexylphosphine, tri-o-benzylphosphine, or a combination thereof.
The invention also provides a preparation method of the nitrogen-containing heterocyclic compound shown in the formula I, which comprises the following steps of d-g:
X is halogen, pg is benzyl or Boc protecting group, and the definition of other groups is as described above;
d) The compound of the general formula (D) and the nitrogen-containing spiro ringOr bridged ring compounds R 1 -H under basic conditions, to produce a compound of formula (N);
e) Reacting a compound of the general formula (E) with an alkyl-substituted hydroxy or amino compound H-L-R under the action of a base 2 Generating a compound of a general formula (F) by substitution reaction;
f) Removing protecting groups from the compound of the general formula (F) by an acid catalysis or transition metal catalysis hydrogenation method to generate a compound of the general formula (G);
g) Coupling reaction of the compound of the general formula (G) with substituted aryl halide or aryl boric acid under the catalysis of transition metal to generate the compound of the general formula (I);
preferably, the steps d), e), f), g) are each carried out in a solvent, and the solvent is selected from the group consisting of: water, methanol, ethanol, isopropanol, butanol, ethylene glycol methyl ether, N-methylpyrrolidone, dimethyl sulfoxide, tetrahydrofuran, toluene, methylene chloride, 1, 2-dichloroethane, acetonitrile, N-dimethylformamide, N-dimethylacetamide, dioxane, or a combination thereof.
Preferably, the inorganic base is selected from the group consisting of: sodium hydride, potassium hydroxide, sodium acetate, potassium t-butoxide, sodium t-butoxide, potassium fluoride, cesium fluoride, potassium phosphate, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, or a combination thereof; the organic base is selected from the group consisting of: pyridine, triethylamine, N, N-diisopropylethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), lithium hexamethyldisilazide, sodium hexamethyldisilazide, lutidine, or combinations thereof.
Preferably, the acid is selected from the group consisting of: hydrochloric acid, hydrofluoric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, formic acid, acetic acid, trifluoromethanesulfonic acid or combinations thereof.
Preferably, the transition metal palladium catalyst is selected from the group consisting of: tris (dibenzylideneacetone) dipalladium (Pd) 2 (dba) 3 ) Tetrakis (triphenylphosphine) palladium (Pd (PPh) 3 ) 4 ) Palladium acetate, palladium chloride, dichloro-bis (triphenylphosphine) palladium, trifluoroacetate, triphenylphosphine palladium acetate, [1,1' -bis (diphenylphosphino) dicyclopentadieneIron (Fe)]Palladium dichloride, bis (triphenylphosphine) palladium dichloride, 1, 2-bis (diphenylphosphino) ethane palladium dichloride, or a combination thereof; the catalyst ligand is selected from the group consisting of: tri-tert-butylphosphine, tri-tert-butylphosphine tetrafluoroborate, tri-n-butylphosphine, triphenylphosphine, tri-p-benzylphosphine, tricyclohexylphosphine, tri-o-benzylphosphine, or a combination thereof.
Preferably, the transition metal copper catalyst is selected from the group consisting of: copper acetate, copper trifluoroacetate, copper sulfate, copper bromide, copper chloride, copper iodide, or a combination thereof.
The necessary starting materials or reagents for preparing the compounds of formula I are commercially available or may be prepared by synthetic methods known in the art. The compounds of the invention may be prepared as free bases or as salts thereof with acids, as described in the experimental section below. The term pharmaceutically acceptable salt refers to a pharmaceutically acceptable salt as defined herein, and has all of the pharmaceutical activity of the parent compound. Pharmaceutically acceptable salts can be prepared by adding the corresponding acid to a suitable organic solvent for the organic base, and processing according to conventional methods.
Examples of salification include: salifying with inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; and salts formed with organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, eurynic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid or trimethylacetic acid.
X is halogen, pg is benzyl or Boc protecting group, and the definition of other groups is as described above; the nitrogen-containing heterocyclic compounds of formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereomers, tautomers, torsional isomers, solvates, polymorphs, or prodrugs thereof, may have one or more chiral carbon atoms, and thus may be isolated as optically pure isomers, e.g., pure enantiomers, or racemates, or mixed isomers. Pure single isomers may be obtained by separation methods in the art, such as chiral crystallization to form salts, or chiral preparative column separation.
The chemicals used in the synthetic routes described in this patent include solvents, reagents, catalysts, and protecting groups, deprotecting groups, including t-butoxycarbonyl (Boc). The above-described methods may additionally include steps prior to or subsequent to the steps specifically described herein, and suitable protecting groups may be added or removed to provide the subject compounds. In addition, the various synthetic steps may be performed alternately or sequentially to obtain the final target product.
It is another object of the present invention to provide a medicament for treating or preventing tumors and a composition thereof. The technical scheme for achieving the purpose is as follows:
the invention provides a pharmaceutical composition comprising an effective amount of a nitrogen-containing heterocyclic compound shown as the formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, and (one or more) pharmaceutically acceptable carrier (pharmaceutical auxiliary materials). For example, such pharmaceutical compositions may comprise one or more additional nitrogen-containing heterocyclic biaryl compounds of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof. In the pharmaceutical composition, the nitrogen-containing heterocyclic biaryl compound shown in the formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof can be used in an amount effective for treatment.
The invention provides a pharmaceutical composition for treating tumors, which consists of a nitrogenous heterocyclic compound shown in the general formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereomers, tautomers, torsional isomers, solvates, polymorphs or prodrugs thereof and a pharmaceutically acceptable carrier.
It is a further object of the present invention to provide the use of the above compounds. The technical scheme for achieving the purpose is as follows:
the invention also provides an application of the nitrogen-containing heterocyclic compound shown in the formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof in preparing Ras mutant protein inhibitor; in the application, the Ras mutant protein can be KRAS G12D The method comprises the steps of carrying out a first treatment on the surface of the The Ras mutein inhibitors are useful in mammalian organisms; it is also useful in vitro, mainly as an experimental use, for example: provides comparison as a standard sample or a control sample, or is prepared into a kit according to a conventional method in the field, and provides rapid detection for the inhibition effect of Ras mutant protein.
The invention also provides an application of the nitrogen-containing heterocyclic compound shown in the formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof in preparing medicines; the medicine can be used for treating diseases related to activity or expression quantity of Ras mutant protein; alternatively, the drug may be a therapeutic drug for tumors. The Ras mutant protein can be KRAS G12D . The tumor is independently selected from non-small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, gastric cancer, intestinal cancer, bile duct cancer, brain cancer, leukemia, lymphoma, fibroma, sarcoma, basal cell carcinoma, glioma, renal cancer, melanoma, bone cancer, thyroid cancer, nasopharyngeal cancer, pancreatic cancer, etc.
Another aspect of the invention relates to a method for preventing and/or treating a disease associated with activity or expression of a Ras mutein, comprising administering to a patient a therapeutically effective amount of the nitrogen-containing heterocyclic compound of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof.
Another aspect of the present invention relates to a method for preventing and/or treating tumors, which comprises administering to a patient a therapeutically effective amount of the nitrogen-containing heterocyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof.
Another aspect of the invention relates to a medicament for preventing and/or treating a disease or tumor associated with activity or expression of a Ras mutein, which comprises the nitrogen-containing heterocyclic compound of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof.
The nitrogen-containing heterocyclic compound shown in the general formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof is used for preparing medicaments for treating diseases related to activity or expression quantity of Ras mutant protein, in particular to medicaments for treating tumors. The tumor is independently selected from non-small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, gastric cancer, intestinal cancer, bile duct cancer, brain cancer, leukemia, lymphoma, fibroma, sarcoma, basal cell carcinoma, glioma, renal cancer, melanoma, bone cancer, thyroid cancer, nasopharyngeal cancer, pancreatic cancer, etc.
The invention relates to a compound with the structural characteristics of a general formula I, which can inhibit various tumor cells, in particular can kill KRAS with high efficiency G12D The tumor related to abnormal mutein signal pathway is a new therapeutic drug with a novel action mechanism.
The pharmaceutical excipients can be those which are widely used in the field of pharmaceutical production. Adjuvants are used primarily to provide a safe, stable and functional pharmaceutical composition, and may also provide means for allowing the subject to dissolve at a desired rate after administration, or for promoting effective absorption of the active ingredient after administration of the composition. The pharmaceutical excipients may be inert fillers or provide a function such as stabilizing the overall pH of the composition or preventing degradation of the active ingredients of the composition. The pharmaceutical excipients can comprise one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, sizing agents, disintegrants, lubricants, anti-adherents, glidants, wetting agents, gelling agents, absorption retarders, dissolution inhibitors, enhancing agents, adsorbents, buffering agents, chelating agents, preservatives, colorants, flavoring agents, and sweeteners.
Substances that may be pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, aluminum stearate, lecithin, serum proteins, such as human serum proteins, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, lanolin, sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; a gum powder; malt; gelatin; talc powder; adjuvants such as cocoa butter and suppository waxes; oils such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycol compounds such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic salt; ringer's solution; ethanol, phosphate buffer, and other non-toxic suitable lubricants such as sodium lauryl sulfate and magnesium stearate, coloring agents, releasing agents, coating materials, sweetening, flavoring and perfuming agents, preserving and antioxidant agents.
The pharmaceutical compositions of the present invention may be prepared in accordance with the disclosure using any method known to those of skill in the art. For example, conventional mixing, dissolving, granulating, emulsifying, levigating, encapsulating, entrapping or lyophilizing processes.
The pharmaceutical dosage forms of the compounds of the present invention may be provided in the form of immediate release, controlled release, sustained release or target drug release systems. For example, common dosage forms include solutions and suspensions, (micro) emulsions, ointments, gels and patches, liposomes, tablets, dragees, soft or hard shell capsules, suppositories, ovules, implants, amorphous or crystalline powders, aerosols and freeze-dried formulations. Depending on the route of administration used, special devices may be required to administer or administer the drug, such as syringes and needles, inhalers, pumps, injection pens, applicators, or Special bottles (Special flash). Pharmaceutical dosage forms often consist of a drug, excipients and a container/sealing system. One or more excipients (also known as inactive ingredients) may be added to the compounds of the present invention to improve or promote the manufacture, stability, administration and safety of the drug, and may provide a means to achieve a desired drug release profile. Thus, the type of excipient added to a drug may depend on various factors, such as the physical and chemical characteristics of the drug, the route of administration, and the manufacturing steps. Pharmaceutically acceptable excipients are present in this field and include those listed in the various pharmacopoeias. (see U.S. Pharmacopeia (U.S.Pharmacopeia, USP), japanese Pharmacopeia (Japanese Pharmacopoeia, JP), european Pharmacopeia (European Pharmacopoeia, EP) and British Pharmacopeia (British pharmacopoeia, BP); U.S. food and drug administration (the U.S. food and Drug Administration, www.fda.gov) drug evaluation and research center (Centerfor Drug Evaluation and Research, CEDR) publications, for example, inactive ingredient guide (Inactive Ingredient Guide, 1996); pharmaceutical additives handbook written by Ash and Ash (Hand book of Pharmaceutical Additives,2002, incorporated information resources, inc. (Synapse Information Resources, inc., endiott NY; etc.).
Pharmaceutical dosage forms of the compounds of the present invention may be manufactured by any of the methods well known in the art, for example by conventional mixing, sieving, dissolving, melting, granulating, dragee-making, tabletting, suspending, extruding, spray-drying, grinding, emulsifying, (nano/micro) encapsulating, packaging, or lyophilizing processes. As noted above, the compositions of the present invention may include one or more physiologically acceptable inactive ingredients that facilitate processing of the active molecule into a formulation for pharmaceutical use.
The pharmaceutical compositions of the invention may be administered topically or systemically, e.g. for enteral, such as rectal or oral administration, or for parenteral administration to a mammal (especially a human), and comprise a therapeutically effective amount of a compound according to the invention, a stereoisomer or a pharmaceutically acceptable salt thereof as active ingredient, together with a pharmaceutically acceptable excipient, such as a pharmaceutically acceptable carrier. A therapeutically effective amount of the active ingredient is defined as above and below and depending on the species, weight, age, individual condition, individual pharmacokinetic parameters, disease to be treated and mode of administration of the mammal, for enteral administration, such as oral administration, the compounds of the invention can be formulated in a wide variety of dosage forms.
The pharmaceutical compositions and dosage forms may comprise one or more compounds of the present invention, stereoisomers thereof, or one or more pharmaceutically acceptable salts thereof, as an active ingredient. The pharmaceutically acceptable carrier may be a solid or a liquid. Solid forms of preparation include powders, tablets, pills, troches, capsules, cachets, suppositories, and dispersible granules. The solid carrier may also be one or more substances that act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is usually a finely divided solid, which is a mixture with the finely divided active component. In tablets, the active ingredient is typically mixed with a carrier having the necessary binding capacity in a suitable ratio and compacted in the shape and size desired. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, methylcellulose, sodium carboxymethylcellulose, low melting waxes, cocoa butter and the like. Formulations of the active compounds may include an encapsulating material as a carrier providing a capsule in which the active ingredient with or without the carrier is surrounded by a carrier to which it is bound.
Other forms suitable for oral administration include liquid form preparations, including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations intended to be converted to liquid form preparations shortly before use. The emulsion may be prepared in solution, for example in an aqueous propylene glycol solution, or may contain an emulsifier such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active ingredient in water and adding suitable colorants, fragrances, stabilizers and thickeners. Aqueous suspensions may be prepared by dispersing the finely divided active component in water with binders such as natural or synthetic gums, resins, methylcellulose, carboxymethylcellulose and other commonly used suspending agents. Solid form preparations include solutions, suspensions and emulsions which may contain, in addition to the active ingredient, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like.
Exemplary combinations for rectal administration include suppositories, which may contain, for example, suitable non-irritating excipients such as cocoa butter, synthetic glycerides or polyethylene glycols, which are solid at ordinary temperatures, but melt and/or dissolve in the rectal cavity to release the drug.
The compounds of the invention may also be administered parenterally, for example, by inhalation, injection or infusion, such as by intravenous, intra-arterial, intra-osseous, intramuscular, intra-cerebral, extra-cerebral, intra-synovial, intra-sternal, intrathecal, intralesional, intracranial, intratumoral, intradermal, and subcutaneous injection or infusion.
Thus, for parenteral administration, the pharmaceutical compositions of the invention may be in the form of sterile injectable or infusible preparations, e.g., as sterile aqueous or oleaginous suspensions. The suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (e.g., tween 80) and suspending agents. The sterile injectable or infusible formulation may also be a sterile injectable or infusible solution or suspension in a non-toxic parenterally acceptable diluent or solvent. For example, the pharmaceutical composition may be a solution in 1, 3-butanediol. Other examples of acceptable vehicles and solvents that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, mannitol, water, ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil may be employed for this purpose including synthetic mono-or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long chain alcohol diluent or dispersant. Solutions for parenteral use may also include suitable stabilizers and, if desired, buffer substances. Suitable stabilizers include antioxidants such as sodium bisulfate, sodium sulfite or ascorbic acid, citric acid and salts thereof and sodium EDTA alone or in combination. The parenteral solution may also contain preservatives such as benzalkonium chloride, parahydroxybenzoic acid or propyl parahydroxybenzoate and chlorobutanol.
For inhalation or nasal administration, suitable pharmaceutical formulation chamber particles, aerosols, powders, mists or droplets, for example, have an average size of about 10 microns or less in diameter. For example, compositions for inhalation may be prepared in saline as solutions, using benzyl alcohol or other suitable preservatives, absorption promoters for improving bioavailability, fluorocarbon and/or other solubilizing or dispersing agents known in the art.
The pharmaceutical compositions of the present invention may also be administered topically to the skin or mucosa. For topical application, the pharmaceutical composition may be, for example, a lotion, gel, paste, tincture, transdermal patch, gel for transmucosal delivery.
The pharmaceutical compositions may be formulated in a suitable ointment comprising the active ingredient suspended or dissolved in a carrier. Carriers for topical administration of the compounds of the invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes and water. Alternatively, the pharmaceutical compositions may be formulated as suitable lotions or emulsions comprising the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of the present invention may also be administered topically to the lower intestinal tract in rectal suppository formulations or in suitable enema formulations. Suitable pharmaceutical excipients (e.g. carriers) and methods for preparing pharmaceutical dosage forms are described in standard reference textbooks in the pharmaceutical formulation arts (Remington's Pharmaceutical Sciences, mack Publishing Company)
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. The limited space is not described in any more detail herein.
Terminology
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety unless otherwise indicated.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the inventive subject matter. In this application, the singular is used to include the plural unless specifically stated otherwise. It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the use of "or" means "and/or" unless stated otherwise. Furthermore, the terms "include," as well as other forms, such as "comprising," "including," and "containing," are not limiting.
The definition of standard chemical terms can be found in references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY TH ED." vols. A (2000) and B (2001), plenum Press, new York). Conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV/VIS spectroscopy, and pharmacological methods are employed unless otherwise indicated. Unless specifically defined otherwise, the terms used herein in the description of analytical chemistry, organic synthetic chemistry, and pharmaceutical chemistry are known in the art. Standard techniques may be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the reaction and purification can be carried out using the manufacturer's instructions for the kit, or in a manner well known in the art or in accordance with the teachings of the present invention. The techniques and methods described above may generally be practiced according to conventional methods well known in the art, based on a number of general and more specific descriptions in the literature cited and discussed in this specification. In this specification, groups and substituents thereof can be selected by one skilled in the art to provide stable moieties and compounds.
When substituents are described by conventional formulas written from left to right, the substituents also include chemically equivalent substituents obtained when writing formulas from right to left. For example, -CH 2 O-is equivalent to-OCH 2 -。
The section headings used herein are for purposes of organizing articles only and should not be construed as limiting the subject matter. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals, and treatises, are hereby incorporated by reference in their entirety.
Certain chemical groups defined herein are preceded by a simplified symbol to indicate the total number of carbon atoms present in the group. For example, C1-6 alkyl, C 1-6 Alkyl or C 1- C 6 Alkyl refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms. The total number of carbon atoms in the reduced notation does not include carbon that may be present in a substituent of the group.
Certain chemical groups defined herein are preceded by a simplified symbol to indicate the total number of carbon atoms present in the group. For example, C1-C6 alkyl refers to an alkyl group as defined below having a total of 1, 2, 3, 4, 5 or 6 carbon atoms. The total number of carbon atoms in the reduced notation does not include carbon that may be present in a substituent of the group.
In this context, a numerical range as defined in substituents, such as 0 to 4, 1-4, 1 to 3, etc., indicates an integer within the range, such as 1-6 is 1, 2, 3, 4, 5, 6.
In the various parts of the invention, linking substituents are described. When the structure clearly requires a linking group, the markush variables recited for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for that variable enumerates an "alkyl" or "aryl" group, it will be understood that the "alkyl" or "aryl" represents a linked alkylene group or arylene group, respectively.
In some specific structures, when an alkyl group is explicitly represented as a linking group, then the alkyl group represents a linked alkylene group, e.g., the group "halo-C 1 -C 6 C in alkyl' 1 -C 6 Alkyl is understood to mean C 1 -C 6 Alkylene (e.g., methylene, ethylene, propylene, butylene, pentylene, isopropylene, isobutylene, sec-butylene, tert-butylene, isopentylene, 2-methylbutylene, 1-ethylpropylene, 1, 2-dimethylpropylene, neopentylene or 1, 1-dimethylpropylene, etc.).
In addition to the foregoing, when used in the specification and claims of this application, the following terms have the meanings indicated below, unless specifically indicated otherwise.
The term "comprising" is an open-ended expression, i.e. including what is indicated by the invention, but not excluding other aspects.
The term "substituted" refers to any one or more hydrogen atoms on a particular atom being substituted with a substituent, including heavy hydrogen and variants of hydrogen, so long as the valence of the particular atom is normal and the substituted compound is stable.
In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced with a specific substituent. Further, when the group is substituted with 1 or more of the substituents, the substituents are independent of each other, that is, the 1 or more substituents may be different from each other or the same. Unless otherwise indicated, a substituent group may be substituted at each substitutable position of the substituted group. When more than one position in a given formula can be substituted with one or more substituents selected from a particular group, then the substituents may be the same or different at each position.
In the various parts of the present specification, substituents of the presently disclosed compounds are disclosed in terms of the type or scope of groups. It is specifically noted that the present invention includes each individual subcombination of the individual members of these group classes and ranges. For example, the term "C 1 ~C 6 Alkyl "or" C 1-6 Alkyl "means in particular methyl, ethyl, C independently disclosed 3 Alkyl, C 4 Alkyl, C 5 Alkyl and C 6 An alkyl group; "C 1-4 Alkyl "refers specifically to independently disclosed methyl, ethyl, C 3 Alkyl (i.e. propyl, including n-propyl and isopropyl), C 4 Alkyl (i.e., butyl, including n-butyl, isobutyl, sec-butyl, and tert-butyl).
In the present application, the term "halogen" refers to fluorine, chlorine, bromine or iodine; "hydroxy" refers to an-OH group; "hydroxyalkyl" refers to an alkyl group as defined below substituted with a hydroxy (-OH); "carbonyl" refers to a-C (=o) -group; "nitro" means-NO 2 The method comprises the steps of carrying out a first treatment on the surface of the "cyano" refers to-CN; "amino" means-NH 2 The method comprises the steps of carrying out a first treatment on the surface of the "substituted amino" refers to an amino group substituted with one or two alkyl, alkylcarbonyl, aralkyl, heteroaralkyl groups as defined below, e.g., mono-, di-, alkylamido, aralkylamino, heteroaralkylamino; "carboxy" means-COOH; "acyl" refers to a-C (=o) H group; "sulfone group" means-S (=O) 2 -a group; "sulfoxide" refers to the-S (=o) -group; "sulfonyl" means-S (=o) 2 An H group; "urea" means-NH-C (=o) -NH 2 The method comprises the steps of carrying out a first treatment on the surface of the "sulfonylurea" means-S (=o) 2 -NH-C(=O)-NH 2 A group; "alkoxy" refers to an alkyl-O-group as defined below.
In the present application, as part of a group or other group (e.g. as used in halogen substituted alkyl groups or the like), the term "alkyl" means a straight or branched hydrocarbon chain group consisting of only carbon atoms and hydrogen atoms, free of unsaturated bonds, having, for example, from 1 to 12 (preferably from 1 to 8, more preferably from 1 to 6) carbon atoms and being linked to the remainder of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl, decyl and the like.
The term "alkylene" as used herein refers to a saturated, branched or straight chain or cyclic hydrocarbon group of the number of carbon atoms (typically 1-6 carbon atoms) and having two monovalent radical centers derived from the removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkane. Typical alkylene groups include, but are not limited to, methylene (-CH) 2 (-) ethylene { including 1, 2-ethylene (-CH) 2 CH 2 (-), 2-dimethylene (-CH (CH) 3 ) (-) } propylene { including 2-methylpropylene (-CH (CH) 3 )CH 2 (-), isopropylidene (-C (CH) 3 ) 2 (-), 1, 3-propylene (-CH) 2 CH 2 CH 2 (-) } butylene { including 1, 4-butylene (-CH) 2 CH 2 CH 2 CH 2 -)}。
In the present application, the term "alkenyl" as part of a group or other group means a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms, containing at least one double bond, having, for example, 2 to 14 (preferably 2 to 10, more preferably 2 to 6) carbon atoms and being linked to the rest of the molecule by a single bond, such as, but not limited to, ethenyl, propenyl, allyl, but-1-enyl, but-2-enyl, pent-1, 4-dienyl, and the like.
In this application, the term "alkynyl" as part of a group or other group means a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms, containing at least one triple bond and optionally one or more double bonds, having, for example, 2 to 14 (preferably 2 to 10, more preferably 2 to 6) carbon atoms and being attached to the remainder of the molecule by a single bond, such as, but not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-en-4-ynyl, and the like.
In this application, as part of a group or other group, the term "cycloalkyl" means a stable, non-aromatic, mono-or polycyclic hydrocarbon group consisting of only carbon and hydrogen atoms, which may include fused ring systems, bridged ring systems, or spiro ring systems, having from 3 to 15 carbon atoms, preferably from 3 to 10 carbon atoms, more preferably from 3 to 8 carbon atoms, and which is saturated or unsaturated and may be attached to the remainder of the molecule by a single bond via any suitable carbon atom. Unless otherwise specifically indicated in the specification, carbon atoms in cycloalkyl groups may optionally be oxidized. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexanyl, cyclooctyl, 1H-indenyl, 2, 3-indanyl, 1,2,3, 4-tetrahydro-naphthyl, 5,6,7, 8-tetrahydro-naphthyl, 8, 9-dihydro-7H-benzocyclohepten-6-yl, 6,7,8, 9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9, 10-hexahydro-benzocyclooctenyl, fluorenyl, bicyclo [2.2.1] heptyl, 7-dimethyl-bicyclo [2.2.1] heptyl, bicyclo [2.2.1] heptenyl, bicyclo [ 2.2.2.2 ] octyl, bicyclo [3.1.1] heptyl, bicyclo [3.2.1] octyl, bicyclo [2.2.2] octenyl, bicyclo [ 2.1.1 ] octadienyl, adamantylene, and the like.
In the present application, the term "heterocyclyl" as part of a group or other group means a stable 3-to 20-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. Unless specifically indicated otherwise in the present specification, a heterocyclyl group may be a monocyclic, bicyclic, tricyclic or more cyclic ring system, which may include fused, bridged or spiro ring systems; the nitrogen, carbon or sulfur atoms in the heterocyclyl may optionally be oxidized; the nitrogen atom may optionally be quaternized; and the heterocyclyl may be partially or fully saturated. The heterocyclic group may be attached to the remainder of the molecule via a carbon atom or a heteroatom and by a single bond. In heterocyclyl groups containing fused rings, one or more of the rings may be aryl or heteroaryl as defined below, provided that the point of attachment to the remainder of the molecule is a non-aromatic ring atom. For the purposes of the present invention, heterocyclyl groups are preferably stable 4-to 11-membered non-aromatic monocyclic, bicyclic, bridged or spiro groups comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably stable 4-to 8-membered non-aromatic monocyclic, bicyclic, bridged or spiro groups comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heterocyclyl groups include, but are not limited to: pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2, 7-diaza-spiro [3.5] nonan-7-yl, 2-oxa-6-aza-spiro [3.3] heptan-6-yl, 2, 5-diaza-bicyclo [2.2.1] heptan-2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxacyclopentyl, tetrahydroisoquinolyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, indolinyl, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidinyl, phthalimidyl, and the like.
In the present application, the term "heterocycloalkyl" means a stable 3-to 20-membered saturated cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur, as part of a group or other groups. Unless otherwise specifically indicated in the present specification, a heterocycloalkyl group may be either a monocyclic ("monocyclic heterocycloalkyl") or a bicyclic, tricyclic or higher ring system, which may include fused, bridged or spiro ring systems (e.g., bicyclic systems ("bicyclic heterocycloalkyl"). The heterocycloalkyl bicyclic ring system may include one or more heteroatoms in one or both rings, and is saturated for purposes of the present invention, a heterocycloalkyl group is preferably a stable 4-to 12-membered saturated monocyclic, bicyclic, bridged or spiro ring group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 4-to 7-membered saturated monocyclic, bicyclic, bridged or spiro ring group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, in particular, the 4-to 7-membered heterocycloalkyl group may contain 3, 4, 5 or 6 carbon atoms and one or two of the heteroatoms or heteroatom-containing groups, provided that the total number of ring atoms is not greater than 7, in particular the heterocycloalkyl group may contain 3, 5 or 6 carbon atoms and the total number of heteroatoms or heteroatom-containing groups ("the total number of heteroatoms may be 3, 5 or 6 heteroatoms").
In this application, the term "aryl" as part of a group or other group means a conjugated hydrocarbon ring system group having 6 to 18 carbon atoms, preferably having 6 to 10 carbon atoms. For the purposes of the present invention, aryl groups may be monocyclic, bicyclic, tricyclic or more ring systems, and may also be fused to cycloalkyl or heterocyclyl groups as defined above, provided that the aryl groups are linked to the remainder of the molecule by single bonds via atoms on the aromatic ring. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, phenanthryl, fluorenyl, 2, 3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1, 4-benzoxazin-3 (4H) -one-7-yl, and the like.
In the present application, the term "arylalkyl" refers to an alkyl group as defined above substituted with an aryl group as defined above.
In this application, as part of a group or other group, the term "heteroaryl" means a 5-to 16-membered conjugated ring system group having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur within the ring. Unless otherwise specifically indicated in the present specification, heteroaryl groups may be monocyclic, bicyclic, tricyclic or more ring systems, and may also be fused to cycloalkyl or heterocyclyl groups as defined above, provided that heteroaryl groups are attached to the remainder of the molecule via an atom on an aromatic ring by a single bond. The nitrogen, carbon, or sulfur atoms in the heteroaryl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. For the purposes of the present invention, heteroaryl groups are preferably stable 5-to 12-membered aromatic groups comprising 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably stable 5-to 10-membered aromatic groups comprising 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur or 5-to 6-membered aromatic groups comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolinyl, isoquinolinyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, benzothienyl, oxatriazolyl, cinnolinyl, quinazolinyl, thiophenyl, indolizinyl, phenanthroline, isoxazolyl, phenoxazinyl, phenothiazinyl, 4,5,6, 7-tetrahydrobenzo [ b ] thienyl, naphthyridinyl, [1,2,4] triazolo [4, 3-triazolo [1, 4] pyridazine, 3-1, 4-imidazo [1, 4] triazolo [1, 4, 3-triazolo [1, 4] pyridazine, 3-1, 4-imidazo [ 2,4] a ] 1, 4-imidazo [ 2, 4-a ] and the like.
In the present application, the term "heteroarylalkyl" refers to an alkyl group as defined above substituted with a heteroaryl group as defined above.
As used herein, the singular forms "a", "an", and "the" are understood to include plural referents unless the context clearly dictates otherwise. Furthermore, the term "comprising" is an open-ended limitation and does not exclude other aspects, i.e. it includes the content indicated by the invention.
Unless otherwise indicated, the present invention employs conventional methods of mass spectrometry, elemental analysis, and the various steps and conditions are referred to in the art by conventional procedures and conditions.
The present invention employs, unless otherwise indicated, standard nomenclature for analytical chemistry, organic synthetic chemistry and optics, and standard laboratory procedures and techniques. In some cases, standard techniques are used for chemical synthesis, chemical analysis, and light emitting device performance detection.
In addition, unless explicitly indicated otherwise, the description of the invention as "…" independently is to be understood broadly as meaning that each individual described may be independent of the other, and may be the same or different. In more detail, the description "… is independently" may mean that specific options expressed between the same symbols in different groups do not affect each other; it may also be expressed that specific options expressed between the same symbols in the same group do not affect each other.
Those skilled in the art will appreciate that, in accordance with convention used in the art, the present application describes the structural formula of a group as used inMeaning that the corresponding group is linked to other fragments, groups in the compound through this site.
In this application, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted aryl" means that the aryl group is substituted or unsubstituted, and the description includes both substituted aryl groups and unsubstituted aryl groups.
The terms "moiety", "structural moiety", "chemical moiety", "group", "chemical group" as used herein refer to a particular fragment or functional group in a molecule. Chemical moieties are generally considered to be chemical entities that are embedded or attached to a molecule.
"stereoisomers" refer to compounds that consist of the same atoms, are bonded by the same bonds, but have different three-dimensional structures. The present invention is intended to cover various stereoisomers and mixtures thereof.
When an olefinic double bond is contained in the compounds of the present invention, the compounds of the present invention are intended to include both E-and Z-geometric isomers unless otherwise specified.
"tautomer" refers to an isomer formed by the transfer of a proton from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the invention are also intended to be included within the scope of the invention.
The compounds of the invention or pharmaceutically acceptable salts thereof may contain one or more chiral carbon atoms and thus may be produced in enantiomers, diastereomers and other stereoisomeric forms. Each chiral carbon atom may be defined as (R) -or (S) -, based on stereochemistry. The present invention is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the invention may be prepared by selecting racemates, diastereomers or enantiomers as starting materials or intermediates. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography.
Conventional techniques for preparing/separating individual isomers include chiral synthesis from suitable optically pure precursors, or resolution of racemates (or racemates of salts or derivatives) using, for example, chiral high performance liquid chromatography, see, for example, gerald gabiz and Martin g.schmid (eds.), chiral Separations, methods and Protocols, methods in Molecular Biology, vol.243,2004; m.stalcup, chiral Separations, annu.rev.animal.chem.3:341-63, 2010; fumigs et al (EDs.), VOGEL' S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY.sup.TH ED, longman Scientific and Technical Ltd., essex,1991,809-816; heller, acc.chem.Res.1990,23,128.
In the present application, the term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
By "pharmaceutically acceptable acid addition salt" is meant a salt with an inorganic or organic acid that retains the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, and the like; organic acid salts include, but are not limited to, formate, acetate, 2-dichloroacetate, trifluoroacetate, propionate, hexanoate, octanoate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, naphthalenedisulfonate, and the like. These salts can be prepared by methods known in the art.
By "pharmaceutically acceptable base addition salt" is meant a salt formed with an inorganic or organic base that is capable of maintaining the bioavailability of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, the following: primary, secondary and tertiary amines, substituted amines including natural substituted amines, cyclic amines and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. These salts can be prepared by methods known in the art.
"polymorphs" refer to the different solid crystalline phases of certain compounds of the present invention in the solid state due to the presence of two or more different molecular arrangements. Certain compounds of the present invention may exist in more than one crystal form, and the present invention is intended to include various crystal forms and mixtures thereof.
In general, crystallization will produce solvates of the compounds of the present invention. The term "solvate" as used herein refers to an aggregate comprising one or more molecules of a compound of the invention and one or more solvent molecules. The solvent may be water, in which case the solvate is a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as hydrates, including monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate, and the like, as well as the corresponding solvated forms. The compounds of the invention may form true solvates, but in some cases may also retain only adventitious water or a mixture of water plus a portion of the adventitious solvent. The compounds of the invention may be reacted in a solvent or precipitated or crystallized from a solvent. Solvates of the compounds of the present invention are also included within the scope of the present invention.
The invention also includes prodrugs of the above compounds. In this application, the term "prodrug" means a compound that can be converted into a biologically active compound of the invention under physiological conditions or by solvolysis. Thus, the term "prodrug" refers to a pharmaceutically acceptable metabolic precursor of a compound of the invention. Prodrugs may not be active when administered to an individual in need thereof, but are converted in vivo to the active compounds of the present invention. Prodrugs are typically rapidly converted in vivo to the parent compounds of the present invention, for example, by hydrolysis in blood. Prodrug compounds generally provide solubility, histocompatibility, or sustained release advantages in mammalian organisms. Prodrugs include known amino protecting groups and carboxyl protecting groups. Specific methods of prodrug preparation can be found in saunnier, m.g., et al, biorg. Med. Chem. Lett.1994,4,1985-1990; greenwald, r.b., et al, j.med.chem.2000,43,475.
In this application, "pharmaceutical composition" refers to a formulation of a compound of the invention with a medium commonly accepted in the art for delivery of biologically active compounds to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote the administration of organisms, facilitate the absorption of active ingredients and further exert biological activity.
The term "pharmaceutically acceptable" as used herein refers to a material (e.g., carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention, and is relatively non-toxic, i.e., the material can be administered to an individual without causing an adverse biological reaction or interacting in an adverse manner with any of the components contained in the composition.
In this application, "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye/colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonizing agent, solvent, or emulsifying agent that is approved by the relevant government regulatory agency as acceptable for human or livestock use.
The "tumor", "cell proliferation abnormality related disease", and the like of the present invention include, but are not limited to, leukemia, gastrointestinal stromal tumor, histiocytic lymphoma, non-small cell lung cancer, pancreatic cancer, lung squamous carcinoma, lung adenocarcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, cervical cancer, ovarian cancer, intestinal cancer, nasopharyngeal cancer, brain cancer, bone cancer, esophageal cancer, melanoma, renal cancer, oral cancer, and the like.
The terms "prevent", "preventing" and "preventing" as used herein include reducing the likelihood of a patient from developing or worsening a disease or condition.
The term "treatment" and other similar synonyms as used herein include the following meanings:
(i) Preventing the occurrence of a disease or disorder in a mammal, particularly when such mammal is susceptible to the disease or disorder, but has not been diagnosed as having the disease or disorder;
(ii) Inhibiting the disease or disorder, i.e., inhibiting its progression;
(iii) Alleviating a disease or condition, i.e., causing the state of the disease or condition to subside; or alternatively
(iv) Alleviating symptoms caused by the disease or condition.
The term "effective amount," "therapeutically effective amount," or "pharmaceutically effective amount" as used herein refers to an amount of at least one agent or compound that is sufficient to alleviate one or more symptoms of the disease or disorder being treated to some extent after administration. The result may be a reduction and/or alleviation of signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for treatment is the amount of a composition comprising a compound disclosed herein that is required to provide clinically significant relief from a disorder. Effective amounts suitable in any individual case can be determined using techniques such as a dose escalation test.
The terms "administering," "administering," and the like as used herein refer to a method capable of delivering a compound or composition to a desired site for biological action. These methods include, but are not limited to, oral routes, duodenal routes, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Application techniques useful in the compounds and methods described herein are well known to those skilled in the art, for example, at Goodman and Gilman, the Pharmacological Basis of Therapeutics, current ed.; pergamon; and Remington's, pharmaceutical Sciences (current edition), mack Publishing co., easton, pa. In preferred embodiments, the compounds and compositions discussed herein are administered orally.
The terms "pharmaceutical combination", "co-administration", "administration of other treatments", "administration of other therapeutic agents" and the like as used herein refer to a pharmaceutical treatment obtained by mixing or combining more than one active ingredient, which includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" refers to the simultaneous administration of at least one compound described herein and at least one synergistic agent to a patient in the form of a single entity or single dosage form. The term "ambulatory combination" refers to the simultaneous administration, co-administration, or sequential administration of at least one compound described herein and at least one synergistic formulation as separate entities to a patient at variable intervals. These also apply to cocktail therapies, for example, administration of three or more active ingredients.
It will also be appreciated by those skilled in the art that in the methods described below, the intermediate compound functional groups may need to be protected by appropriate protecting groups. Such functional groups include hydroxyl, amino, mercapto and carboxylic acid. Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl groups (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino groups include t-butoxycarbonyl, benzyloxycarbonyl and the like. Suitable mercapto protecting groups include-C (O) -R "(wherein" R "is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl, and the like. Suitable carboxyl protecting groups include alkyl, aryl or aralkyl esters.
Protecting groups may be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Greene, t.w. and p.g.m. wuts, protective Groups in Organic Synthesis, (1999), 4th Ed. The protecting group may also be a polymeric resin.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that: provides a nitrogen-containing heterocyclic compound which can be used as KRAS G12D An inhibitor; it can be used for preparing antitumor drugs, and preventing and/or treating tumor.
Detailed Description
The inventor prepares a class of nitrogen-containing heterocyclic compounds with novel structure shown in formula I through long-term and intensive research, and discovers that the nitrogen-containing heterocyclic compounds have better KRAS inhibition effect G12D Protein inhibitory Activity and said Compounds are useful in lower concentrations (as low as less than 500 nM), i.e. against KRAS G12D The associated cell proliferation and downstream signal pERK inhibitory activity were quite excellent (IC 50 Even less than 100 nM), and thus can be used in therapy with KRAS G12D Related diseases such as tumor caused by mutation or abnormal expression. Based on the above findings, the inventors have completed the present invention.
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications. The experimental methods in the following examples, in which specific conditions are not noted, are generally in accordance with conventional conditions, or in accordance with the conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Intermediate A1: 7-bromo-2, 4, 6-trichloro-8-fluoroquinazoline
Step one: 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid (1.5 g,5.62 mmol) and urea (2.7 g,44.9 mmol) were mixed and heated to 200℃for 4 hours. Cooled to room temperature, then water (50 mL) was added, heated to 100 ℃ and stirred for an additional hour, filtered while hot. The solid was slurried with ethyl acetate (50 mL) and the filtered solid dried to give a reddish brown intermediate product (1.3 g). LC-MS [ M-H ]] - :m/z 292.9。 1 H NMR(400MHz,DMSO-d 6 ):δ11.50-11.3(dt,2H),7.83(s,1H)。
Step two: the above intermediate compound (413 mg,1.41 mmol) was suspended in POCl 3 To (20 mL) was added three drops of N, N-dimethylaniline, heated at reflux overnight, dried, the residue was dissolved in DCM (10 mL), and saturated NaHCO was added dropwise 3 In water and kept at pH 7-8, extracted three times with DCM (30 mL). The combined organic phases were dried over MgSO 4 Dried, filtered, and concentrated under reduced pressure to give intermediate A1 (219 mg) as a yellow solid. LC-MS [ M+H ]] + :m/z 328.8/330.8。 1 HNMR(400MHz,DMSO-d 6 ):δ8.05(s,1H)。
Referring to the synthetic routes and methods of patents WO2021041671A1 and WO2021118877A1, the following intermediate compounds A2, B1-B3 are prepared;
intermediate C1:1- ((1- (hydroxymethyl) cyclopropyl) methyl) -4-methyl-1, 4-azaphospha-hex-4-oxide
Step one: under nitrogen, methylphosphoryl dichloride (3.97 g,30.1 mmol) was added to a solution of tetrahydrochysene The furan solution (50 mL) was cooled to-78 degrees, then vinylmagnesium bromide (2M, 35mL,70 mmol) was slowly added. After continuing the stirring reaction at this temperature for one hour, ethanol (10 mL) was added, followed by warming and stirring overnight. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: dichloromethane/ethanol=30/1) to obtain an intermediate compound (3.1 g) as a white oil. 1 H NMR(400MHz,DMSO-d 6 ):δ6.07-6.38(m,6H),1.61(d,J=7.2Hz,3H)。
Step two: to an ethanol solution (30 mL) of the intermediate compound (0.8 g,6.85 mmol) under nitrogen was added benzylamine (733 mg,6.85 mmol). The reaction mixture was heated to 100 degrees and reacted overnight. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: dichloromethane/ethanol=25/1) to give an intermediate compound (750 mg) as a white oil. LC-MS [ M+H ]] + :m/z 224.1。 1 H NMR(400MHz,CDCl3):δ7.26-7.38(m,5H),3.71-3.73(m,2H),2.96-3.01(m,2H),2.63-2.65(m,2H),1.86-1.99(m,4H),1.39(d,J=7.2Hz,3H)。
Step three: to the above intermediate compound (750 mg,3.36 mmol) in dichloroethane (10 mL) was added 1-chloroethyl chloroformate (578mg, 4.03 mmol) under nitrogen. The reaction mixture was heated to 100 degrees and stirred overnight. The reaction mixture was concentrated under reduced pressure, the crude product was dried and slurried with petroleum ether, and the filtered solid was dried to give 4-methyl-1, 4-azaphospha-hexylene 4-oxide hydrochloride (380 mg). LC-MS [ M+H ] ] + :m/z 134.1。
Step four: to dichloroethane (50 mL) of cyclohexane-1, 1-dimethanol (5.11 g,50.1 mmol) under nitrogen was added imidazole (7.5 g,110.2 mmol) and tert-butyldiphenylsilicon chloride (13.8 g,50.1 mmol). The reaction mixture was stirred at room temperature for 6 hours. The reaction mixture was washed twice with saturated brine (30 mL), and the separated organic phase was dried over anhydrous sodium sulfate. The filtered organic phase was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=10:1) to give the intermediate product (12.6 g) as a white solid. LC-MS [ M+H ]] + :m/z 341.2。
Step five: in a solution of the above intermediate (3 g,8.8 mmol) in methylene chloride (30 mL) under nitrogenMethanesulfonyl chloride (1.04 g,9.1 mmol) and triethylamine (1.87 g,18.5 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. To the reaction mixture was added saturated aqueous sodium bicarbonate (20 mL). The separated organic phase was washed twice with saturated brine (20 mL) and dried over anhydrous sodium sulfate. The filtered organic phase was concentrated under reduced pressure to give the crude oily intermediate product (2.6 g). LC-MS [ M+H ]] + :m/z 419.2。
Step six: to a solution of the above intermediate (910 mg,2.2 mmol) in N, N-dimethylformamide (10 mL) under nitrogen was added 4-methyl-1, 4-azaphospha-hexylene 4-oxide hydrochloride (380 mg,2.2 mmol) and potassium carbonate (695 mg,5.0 mmol). The reaction mixture was stirred at 50 degrees overnight. After adding water (50 mL) to the reaction solution, extraction was performed twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=8:1) to give intermediate (150 mg) as a white solid. LC-MS [ M+H ] ] + :m/z 456.2。
Step seven: to a solution of the above intermediate (150 mg,0.33 mmol) in methanol (10 mL) was added ammonium fluoride (40 mg,1.1 mmol). The reaction mixture was stirred at 60 degrees for 3 hours. TLC detection reaction was complete. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to give an intermediate (43 mg) as a white solid. LC-MS [ M+H ]] + :m/z 218.2。 1 H NMR(400MHz,DMSO):δ4.40(br.s,1H),3.30(s,2H),2.93-2.83(m,2H),2.59-2.55(m,2H),2.36(s,2H),1.81-1.67(m,4H),1.42-1.38(m,3H),0.43-0.40(m,2H),0.23-0.21(m,2H)。
Intermediate C2:1- ((1- (hydroxymethyl) cyclopropyl) methyl) -4-cyclopropyl-1, 4-azaphospha-hex-4-oxide
Referring to the synthesis method of the intermediate C1, the intermediate C2 is prepared by replacing methyl phosphoryl dichloride with cyclopropyl phosphoryl dichloride. LC-MS [ M+H ]] + :m/z 218.2。 1 H NMR(400MHz,DMSO):δ4.42(br.s,1H),3.32(s,2H),2.93-2.85(m,2H),2.61-2.54(m,2H),2.35(s,2H),1.81-1.67(m,4H),1.39(m,1H),0.75-0.71(m,2H),0.66-0.59(m,2H),0.43-0.41(m,2H),0.31-0.28(m,2H)。
Intermediate C3:4- ((1- (hydroxymethyl) cyclopropyl) methyl) -1- (methylimino) -1λ 6 -thiomorpholine-1-oxide
Step one: to a solution of tert-butyl 1-iminothiomorpholine-4-carboxylate (3.7 g,15.8 mmol) in tetrahydrofuran (50 mL) under nitrogen was added potassium carbonate (4.45 g,32.2 mmol) and methyl iodide (2.27 g,16.0 mmol). The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10/1) to obtain an intermediate compound (3.1 g) as a white solid. LC-MS [ M+H ] ] + :m/z 249.1。
Step two: to a solution of the above intermediate (3.1 g,12.5 mmol) in methylene chloride (20 mL) was added trifluoroacetic acid (2 mL,26.9 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give a crude white solid compound (2.3 g). LC-MS [ M+H ]] + :m/z 149.0。
Step three: referring to the sixth preparation of intermediate C1, the synthesis of 4-methyl-1, 4-azaphospha-hexylene 4-oxide hydrochloride using the above intermediate replaced a white solid compound (1.6 g). LC-MS [ M+H ]] + :m/z 471.1。
Step four: referring to the seventh preparation of intermediate C1, removal of the protecting group from the above intermediate gave C3 compound as a white solid (450 mg). LC-MS [ M+H ]] + :m/z 471.1。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.36(s,2H),2.93-2.83(m,2H),2.65-2.55(m,5H),2.36(s,2H),1.81-1.67(m,4H),0.43-0.40(m,2H),0.23-0.21(m,2H)。
Intermediate C4:4- ((1- (hydroxymethyl) cyclopropyl) methyl) -1- (cyclopropylimino) -1λ 6 -thiomorpholine-1-oxide
Referring to the synthesis of intermediate C3, intermediate C4 was prepared by substituting iodocyclopropane for methyl iodide. LC-MS [ M+H ]] + :m/z 259.1。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.36(s,2H),2.93-2.83(m,2H),2.65-2.55(m,3H),2.36(s,2H),1.81-1.67(m,4H),0.81-0.57(m,4H),0.43-0.40(m,2H),0.23-0.21(m,2H)。
Intermediate C5: n-4- ((1- (hydroxymethyl) cyclopropyl) methyl) -1-oxide-1λ 6 -thiomorpholin-1-ylidene) aminonitriles
Step one: to a solution of thiomorpholine-4-carboxylic acid benzyl ester (3.6 g,14.8 mmol), cyanamide (0.59 g,15.5 mmol) and potassium tert-butoxide (1.8 g,16.0 mmol) in ethanol (20 mL) was added N-bromosuccinimide (2.85 g,16.1 mmol). The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to obtain a yellow solid intermediate compound (1.1 g). LC-MS [ M+H ] ] + :m/z 278.1。
Step two: to an ethanol solution (10 mL) of the above intermediate compound (1.1 g,4.0 mmol) were added m-chloroperoxybenzoic acid (1.40 g,8.1 mmol) and potassium carbonate (1.17 g,8.5 mmol). The reaction mixture was stirred at room temperature overnight. After 50mL of water was added to the reaction mixture, the reaction mixture was extracted three times with ethyl acetate (30 mL). The combined organic phases were concentrated under reduced pressure and the resulting crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=1:1) to give the compound as a white solid (470 mg). LC-MS [ M+H ]] + :m/z 294.0。
Step three: to an ethanol solution (5 mL) of the above intermediate compound (470 mg,1.6 mmol) was added 5% palladium on carbon (55 mg,0.5 mmol). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (1 atm) overnight. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to give a white solid compound (120 m)g)。LC-MS[M+H] + :m/z 160.0。
Step four: referring to the sixth preparation of intermediate C1, the above intermediate was used in place of 4-methyl-1, 4-azaphospha-hexylene 4-oxide hydrochloride to synthesize a white solid compound (150 mg). LC-MS [ M+H ]] + :m/z 482.2。
Step five: referring to the seventh preparation of intermediate C1, removal of the protecting group from the above intermediate gave C5 compound as a white solid (40 mg). LC-MS [ M+H ]] + :m/z 244.0。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.37(s,2H),2.93-2.83(m,2H),2.68-2.55(m,2H),2.32(s,2H),1.83-1.65(m,4H),0.45-0.40(m,2H),0.26-0.22(m,2H)。
Intermediate C6: (1- (selenomorphlmethyl) cyclopropyl) methanol
Step one: to an anhydrous ethanol suspension (30 mL) of selenium powder (3.95 g,49.4 mmoL) was slowly added sodium borohydride (1.9 g,50.3 mmoL) at-10℃under nitrogen. After the reaction mixture became clear, sodium hydroxide (2.1 g,52.5 mmol) was added in portions to the reaction solution, and stirring was continued for 30 minutes. A solution of bis (2-chloroethyl) amine (7.08 g,50.2 mmol) in ethanol (5 mL) was slowly added to the reaction mixture, and the mixture was heated under reflux for 6 hours. After the reaction solution was cooled to room temperature, the reaction solution was filtered, distilled under reduced pressure, and the low-boiling point solvent was removed to obtain a crude intermediate compound (2.5 g) as a colorless oil. LC-MS [ M+H ]] + :m/z 151.1。
Step two: to a dichloromethane solution of the above intermediate (2.5 g,16.5 mmol) under nitrogen, 1- (chloroformyl) cyclopropane-1-ethyl carbonate (2.90 g,16.5 mmol) and triethylamine (3.34 g,33.0 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=1:4) to obtain a colorless oily compound (3.6 g). LC-MS [ M+H ]] + :m/z 292.0。
Step three: under nitrogen, the intermediate (3.6 g,12.4mAfter the temperature of the tetrahydrofuran solution (50 mL) was lowered to-70℃and lithium aluminum hydride (1.41 g,37.3 mmol) was added thereto in portions. After stirring the reaction mixture at this temperature for 30 minutes, it was slowly warmed to room temperature and stirred overnight. The LC-MS detection reaction was substantially complete. After the reaction solution was cooled to zero, ethyl acetate (20 mL) was added to the reaction solution, and the mixture was slowly warmed to room temperature and stirred for half an hour. Then, water (1.4 g) was slowly added to the reaction solution, sodium hydroxide (0.14 g) and water (4.2 g) were further added, the reaction mixture was stirred for several minutes, then, filtration was carried out, the filtrate was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=1:2) to give an intermediate C6 compound (2.1 g) as a colorless oil. LC-MS [ M+H ] ] + :m/z 236.0。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.39(s,2H),2.93-2.85(m,2H),2.68-2.57(m,2H),2.32(s,2H),1.53-1.44(m,4H),0.48-0.43(m,2H),0.28-0.24(m,2H).
Intermediate C7:4- ((1- (hydroxymethyl) cyclopropyl) methyl) selenomorph 1-oxide
Step one: to a methanol solution (5 mL) of intermediate C6 (500 mg,2.1 mmol) was added a 30% hydrogen peroxide solution (5 mL). The reaction mixture was stirred at room temperature for 3 hours. To the reaction solution were added ethyl acetate (30 mL) and water (20 mL). The separated organic phase was washed three times with water and then concentrated under reduced pressure. The resulting crude product was dried to give intermediate C7 compound (340 mg) as a white solid. LC-MS [ M+H ]] + :m/z 252.0。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.39(s,2H),2.93-2.85(m,2H),2.68-2.57(m,2H),2.32(s,2H),1.93-1.77(m,4H),0.47-0.41(m,2H),0.29-0.23(m,2H).
Intermediate C8: (1- (4, 4-dimethyl-1, 4-azasilan-1-yl) methyl) cyclopropyl) methanol
Referring to the synthetic method of intermediate C6,the intermediate C8 compound was prepared as a colourless oil. LC-MS [ M+H ]] + :m/z 214.2。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.39(s,2H),2.93-2.85(m,2H),2.68-2.57(m,2H),2.32(s,2H),0.75-0.65(m,4H),0.47-0.41(m,2H),0.29-0.23(m,2H),0.19-0.16(s,6H).
Intermediate C9: (1- (8-aza-5-silaspiro [4.5] sunflower-8-yl) methyl) cyclopropyl) methanol
Referring to the synthesis of intermediate C6, a colorless oily intermediate C9 compound was prepared. LC-MS [ M+H ]] + :m/z 214.2。 1 H NMR(400MHz,DMSO):δ4.43(br.s,1H),3.39(s,2H),2.93-2.85(m,2H),2.68-2.57(m,2H),2.32(s,2H),0.95-0.65(m,8H),0.47-0.41(m,2H),0.29-0.23(m,2H),0.19-0.16(s,4H).
Intermediate A3: 7-bromo-2, 6-dichloro-5, 8-difluoroquinazolin-4-ol
Step one: to a solution of 2-amino-4-bromo-3, 6-difluorobenzoic acid (7.0 g,27.9 mmol) in concentrated sulfuric acid (85 mL) was added N-chlorosuccinimide (7.5 g,55.8 mmol). The reaction mixture was stirred at 80℃for 16 hours. The reaction solution was cooled to room temperature, and the reaction solution was slowly added to ice water. The precipitate formed was filtered and after washing the filter cake with water, dried in vacuo to give a grey solid (5.2 g). LC-MS [ M+H ] ] + :m/z287.8/285.8。
Step two: to a solution of the above intermediate compound (5.2 g,18.3 mmol) in tetrahydrofuran (300 mL) were added carbonylimidazole (5.9 g,36.6 mmol) and triethylamine (7.5 g,74.1 mmol). The reaction mixture was stirred at 50℃for 2 hours, cooled to room temperature and ammonium chloride (2.1 g,39.2 mmol) was slowly added. The reaction mixture was stirred at room temperature for a further 16 hours. After the water quenching reaction, most of the organic solvent is removed under reduced pressure. The aqueous phase was extracted with ethyl acetate (300 mL), the separated organic phase was concentrated under reduced pressure, and the crude product was chromatographed on a silica gel column (elution)The preparation method comprises the following steps: petroleum ether/ethyl acetate=3:1) to afford intermediate (4.2 g) as a grey solid. LC-MS [ M+H ]] + :m/z 286.0。
Step three: triphosgene (4.69 g,15.8 mmol) was added to a tetrahydrofuran solution (250 mL) of the above intermediate compound (4.2 g,14.7 mmol), and the reaction mixture was stirred at 70℃for 2 hours. After cooling to room temperature, water is added to quench the reaction, and the organic solvent is removed by decompression concentration. The aqueous phase was extracted with ethyl acetate and the separated organic phase was concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=1:1) to give compound as a white solid (2.8 g). LC-MS [ M+H ]] + :m/z 312.8。
Step four: to a solution of the intermediate compound (2.7 g,9.3 mmol) in phosphorus oxychloride (100 mL) was added N, N-diisopropylethylamine (4 mL). The reaction mixture was stirred at ll0℃for 3 hours. After the reaction solution was cooled to room temperature, it was concentrated under reduced pressure, and the residue was diluted with methylene chloride (50 mL) and then washed with saturated sodium bicarbonate water. The separated organic phase was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=4:1) to give the compound as a grey solid (2.3 g). LC-MS [ M+H ] ] + :m/z 350.5。
Step five, to a tetrahydrofuran solution (100 mL) of the above intermediate compound (2.3 g,6.6 mmol) was added an aqueous sodium bicarbonate solution (2M, 5.5mL,11 mmol) with ice-water bath cooling. The reaction mixture was stirred at room temperature for 3 hours. After the LC-MS detection reaction was substantially complete, the pH of the solution was adjusted to approximately 7 with 1M aqueous hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate (200 mL) and the combined organic phases concentrated under reduced pressure. The crude product obtained was purified by column chromatography on silica gel (eluent: dichloromethane/methanol=10/1) to give an off-white solid A3 intermediate compound (1.3 g). LC-MS [ M+H ]] + :m/z 330.8。
Intermediate A4:2,4,5, 7-tetrachloro-8-fluoropyrido [4,3-d ] pyrimidine
Step one: n, N-dimethyl to 2, 6-dichloropyridin-4-amine (5.1 g,31.3 mmol)To a mixture of formamide (30 mL) and acetic acid (20 mL) was added SelectFuor (13.3 g,37.6 mmol). The reaction mixture was heated to 80 degrees and reacted for half an hour. The LC-MS detection reaction was essentially complete. The reaction mixture was diluted with water (50 mL), and extracted twice with ethyl acetate (50 mL). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The crude product obtained was purified by silica gel column chromatography (ethyl acetate/petroleum ether=1:5) to give intermediate compound (3.2 g) as a white solid. LC-MS [ M+H ] ] + :m/z 183.0/181.0。
Step two: to a solution of the above intermediate compound (3.2 g,17.7 mmol) in methylene chloride (30 mL) was added di-tert-butyl dicarbonate (8.2 g,37.4 mmol), 4-dimethylaminopyridine (457 mg,3.74 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether=1:5) to give a white solid compound (4.5 g). LC-MS [ M+H ]] + :m/z 381.1/383.1。
Step three: lithium diisopropylamide (2M, 11.8mL,23.6 mmol) was slowly added dropwise to a tetrahydrofuran solution (30 mL) of the above intermediate compound (4.5 g,11.8 mmol) at-78 ℃. After 2 hours of reaction at this temperature, the reaction mixture was slowly warmed to room temperature. To the reaction mixture was added water (20 mL) to quench the reaction. The reaction mixture was concentrated under reduced pressure to remove most of the organic solvent, and then extracted twice with ethyl acetate (30 mL). The combined organic phases were concentrated under reduced pressure and the resulting crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether=1:5) to give the intermediate compound (2.7 g) as a yellow solid. LC-MS [ M+H ]] + :m/z 381.1/383.1。 1 H NMR(400MHz,DMSO-d6):δ10.1(s,lH),1.53(s,9H),1.45(s,9H)。
Step four: to a solution of the intermediate compound (2.7 g,7.1 mmol) in methylene chloride (60 mL) was added trifluoroacetic acid (30 mL). The reaction mixture was stirred at room temperature for 16 hours and monitored by LC-MS for completion. The reaction solution was concentrated under reduced pressure to give a yellow solid compound (1.3 g). LC-MS [ M+H ] ] + :m/z 225.0/227.0。
Step five: to an ethanol solution (50 mL) of the above intermediate compound (1.3 g,5.77 mmol) was added concentrated sulfuric acid (5 mL). The reaction mixture was heated to 8The reaction was carried out overnight at 0 ℃. After the reaction solution was cooled to room temperature, a saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the pH of the solution was adjusted to neutral. The reaction solution was extracted with ethyl acetate, and the separated organic phase was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: ethyl acetate/petroleum ether=1:3) to obtain a yellow solid intermediate compound (1.28 g). LC-MS [ M+H ]] + :m/z 253.0/255.0。
Step six: to a solution of the above intermediate compound (1.28 g,5.06 mmol) in tetrahydrofuran (10 mL) was added trichloroacetyl isocyanate (1.91 g,10.1 mmol), and the reaction mixture was stirred at room temperature for 3 hours. LC-MS monitored reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to give a white solid compound (1.89 g). LC-MS [ M+H ]] + :m/z 441.5/443.5。
Step seven: to a methanolic solution (20 mL) of the above intermediate compound (1.89 g,4.28 mmol) was added a methanolic solution (5M, 3mL,15 mmol) of ammonia. The reaction mixture was stirred at room temperature for 4 hours. LC-MS monitored reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give a white solid compound (0.82 g). LC-MS [ M+H ] ] + :m/z 250.0/252.0。
Step eight: the above intermediate compound (0.82 g,3.28 mmol) was dissolved in phosphorus oxychloride (30 mL). After the addition of N, N-diisopropylethylamine (0.64 g,4.92 mmol) at room temperature, the reaction mixture was heated to 100℃and stirred overnight. LC-MS monitored completion of the reaction, and the reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: ethyl acetate/petroleum ether=1:4) to give intermediate compound (0.68 g) as a white solid. LC-MS [ M+H ]] + :m/z 287.5/285.5。
Intermediate A5:2- (hydroxymethyl) -3, 8-diazabicyclo [3.2.1] octane-8-carboxylic acid tert-butyl ester
Step one: under the protection of nitrogen, 8- (tertiary butyl) -2-ethyl-4-oxo-3, 8-diazabicyclo [3 ] compound.2.1]To a solution of octane-2, 8-dicarboxylic acid ester (5.0 g,16.7 mmol) in tetrahydrofuran (300 mL) was added borane in dimethyl sulfide complex (2M, 25mL,50 mmol). The reaction mixture was stirred at room temperature for 18 hours. Methanol (50 mL) was added to the reaction mixture, and the mixture was heated to 50℃and stirred overnight. After the reaction solution was cooled to room temperature, the reaction solution was concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=2:1) to give compound as a white solid (3.3 g). LC-MS [ M+H ]] + :m/z 285.2。
Step two: a solution of the intermediate compound (3.3 g,11.6 mmol) in tetrahydrofuran (250 mL) was cooled to-20℃under nitrogen. Lithium aluminum hydride (660 mg,17.4 mmol) was added in portions to the reaction solution at this temperature. The reaction mixture was kept at below zero for 1 hour and then slowly warmed to room temperature. After LC-MS detects the disappearance of the raw materials, the reaction solution is reduced to zero, and 5mL of water is slowly added into the reaction solution for quenching reaction. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=1:2) to give intermediate A5 compound (1.1 g) as a white solid. LC-MS [ M+H ] ] + :m/z 243.2。
Example general preparation method 1
The first step: the intermediate compound A (1 eq.) is dissolved in a suitable solvent and an amine or alcohol intermediate R is added 1 -H (1.05 eq.) and organic base (3.5 eq.). The reaction was slowly warmed to room temperature and stirred overnight. LC-MS monitors the reaction completely, water is added into the reaction solution, the water phase is extracted three times by ethyl acetate, the extract is dried by anhydrous sodium sulfate, the concentration is reduced, the remainder is separated and purified to obtain the target product, and the structure is confirmed by nuclear magnetism and mass spectrum.
And a second step of: by reacting amines or alcohols as intermediates R 2 L-H (1 eq.) is dissolved in a suitable solvent, an inorganic base (2 eq.) is added with low temperature cooling, and after stirring for half an hour, the intermediate of the above-mentioned first step product formula (B) is added. The reaction was then stirred at room temperature overnight. TLC monitoring of completion of the reaction, water quenchingAfter the sterilization, the mixture is concentrated under reduced pressure, and the residue is prepared, separated and purified by silica gel column chromatography or HPLC to obtain the target compound, and the structure is confirmed by nuclear magnetism and mass spectrum.
And a third step of: under nitrogen protection, the above general formula product C (1 eq.) and arylboronic acid (ester) or arylmetal reagent (1.2 eq.) are dissolved in a suitable solvent, a transition metal catalyst (0.1 eq.) and an inorganic base (2 eq.) are added, heated to 80-100 degrees for several hours of reaction, cooled to room temperature, the reaction solution is poured into water and extracted with ethyl acetate. The organic phase is washed by saturated saline, and after concentration, the crude product is prepared, separated and purified by silica gel column chromatography or HPLC to obtain the target compound, and the structure is confirmed by nuclear magnetism and/or mass spectrum.
Example general preparation method 2
The first step: the intermediate compound A (1 eq.) is dissolved in a suitable solvent and an amine or alcohol intermediate R is added 1 -H (1.05 eq.) and organic base (2 eq.). The reaction was slowly warmed to room temperature and stirred overnight. LC-MS monitors the reaction completely, water is added into the reaction solution, the water phase is extracted three times by ethyl acetate, the extract is dried by anhydrous sodium sulfate, the concentration is reduced, the remainder is separated and purified to obtain the target product, and the structure is confirmed by nuclear magnetism and mass spectrum.
And a second step of: intermediate compound B (1 eq.) was dissolved in an appropriate solvent, and an inorganic base (1.5 eq.) and a palladium transition metal catalyst (0.2 eq.) were added, and the phosphine ligand (0.2 eq.) was heated for several hours. The LC-MS detection reaction was substantially complete. The reaction liquid is filtered by diatomite, washed by organic solvent, and after the filtrate is decompressed and concentrated, the crude product is separated and purified to obtain the target product, and the structure is confirmed by nuclear magnetism and mass spectrum.
And a third step of: intermediate compound C (1 eq.) was dissolved in an appropriate solvent and palladium on carbon (0.1 eq.) was stirred at room temperature under hydrogen atmosphere for several hours. After the LC-MS detection reaction was substantially complete, the celite was filtered. Washing with organic solvent, concentrating the combined organic phases under reduced pressure, separating and purifying the obtained crude product to obtain the target product, and confirming the structure by adopting nuclear magnetism and mass spectrum.
Fourth step: intermediate compound D (1 eq.) was dissolved in an appropriate solvent, substituted aryl boronic acid (ester) (1.2 eq.) was added and the ketone acetate (0.5 eq.) was reacted overnight at room temperature. Or the above intermediate compound F (1 eq.) is dissolved in an appropriate solvent, and the substituted aryl halide (1 eq.) and the transition metal Pd complex (0.2 eq.) are added and reacted under nitrogen with heating for several hours. The LC-MS detection reaction was essentially complete. Concentrating the reaction liquid under reduced pressure, separating and purifying the obtained crude product to obtain a target product, and confirming the structure by adopting nuclear magnetism and mass spectrum.
Example general preparation method 3
The first step: intermediate compound a (1 eq.) is dissolved in an appropriate solvent and amine or alcohol intermediate B (1.05 eq.) and inorganic base (2 eq.) are added. The reaction was slowly warmed to room temperature and stirred overnight. LC-MS monitors the reaction to be complete, water is added into the reaction solution, the water phase is extracted three times by ethyl acetate, the extract is dried by anhydrous sodium sulfate, the concentration is reduced, and the remainder is separated and purified to obtain a target product (C), and the structure is confirmed by nuclear magnetism and mass spectrum.
And a second step of: intermediate C (1.0 eq) was dissolved in an appropriate solvent and an appropriate halogenating reagent (3.0 eq) was added. The reaction is heated to 60 to 100 ℃ for reaction for several hours, and after post-treatment. The crude product is prepared and purified to obtain a target product (D), and a structure is confirmed by adopting nuclear magnetism and mass spectrum.
In the third step, the intermediate (D) (1.0 eq) of the previous step was dissolved in an appropriate solvent, and a base (1.2 eq) was added. The reaction mixture was stirred at room temperature overnight. After the LC-MS detection reaction is completed, preparing and purifying a crude product obtained after the post-treatment of the reaction liquid to obtain a target compound (E), and confirming a structure by adopting nuclear magnetism and mass spectrum.
Fourth step: the product of the above step, general formula (E), was dissolved in a suitable solvent, arylboronic acid (ester) or arylmetal reagent (1.2 eq.) was added, and a transition metal catalyst (0.1 eq.) and inorganic base (2 eq.) were added, and the reaction was heated to 80 to 100℃for several hours, and the LC-MS detection was completed. After the post-treatment of the reaction liquid, the obtained crude product is prepared and purified to obtain the target compound (F), and the structure is confirmed by adopting nuclear magnetism and mass spectrum.
Fifth step: by reacting amines or alcohols as intermediates R 2 L-H (1 eq.) is dissolved in a suitable solvent, an inorganic base (2 eq.) is added with low temperature cooling, and after stirring for half an hour, the intermediate of formula (F) is added as a product of the previous step. The reaction was then stirred at room temperature overnight. TLC monitoring reaction is complete, water quenching is carried out, decompression concentration is carried out, the residue is prepared and separated and purified by silica gel column chromatography or HPLC to obtain the target compound (G), and nuclear magnetism and mass spectrum are adopted to confirm the structure.
And sixth, dissolving the product of the general formula (G) in a proper solvent, and hydrogenating to remove the protecting group on the amino group under the catalysis of acid or palladium. After the reaction post-treatment, preparing and purifying the crude product to obtain the target compound (I), and confirming the structure by adopting nuclear magnetism and mass spectrum.
Example 1:1- ((1- (((4- (3, 8-diazabicyclo [3.2.1] oct-3-yl) -6-chloro-7- (8-ethyne-7-fluoro-3-hydroxynaphthalen-1-yl) -8-fluoroquinazolin-2-yl) oxy) methyl) cyclopropyl) methyl) -4-methyl-1, 4-azaphospha-hex-4-oxide
The first step: to intermediate A1 (275 mg,0.84 mmol) in dichloromethane DCM (15 mL) was added 3, 8-diazabicyclo [3.2.1]Tert-butyl octane-8-carboxylate (178 mg,0.84 mmol) and triethylamine TEA (0.5 mL,4.20 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=1:1) to give a yellow solid product (213 mg) LC-MS [ M+H)] + :m/z 505.0/507.0。
And a second step of: to a suspension of sodium hydride NaH (20 mg,0.50 mmol) in tetrahydrofuran (10 mL) at zero degrees was added intermediate C1 (108 mg,0.50 mmol). After the reaction mixture was stirred at this temperature for half an hour, a solution of the intermediate product of the previous step (213 mg,0.42 mmol) in tetrahydrofuran (3 mL) was added. Reaction The mixture was stirred at room temperature for 3 hours. The LC-MS detection reaction was essentially complete. To the reaction solution was added a saturated aqueous ammonium chloride solution (50 mL), followed by extraction three times with ethyl acetate (50 mL). The combined organic phases were dried and concentrated under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: dichloromethane/methanol=30:1) to give the product as a yellow solid (210 mg). LC-MS [ M+H ]] + :m/z 686.1/688.1。
And a third step of: to a solution of the above intermediate (105 mg,0.15 mmol) in 1, 4-dioxane/water (12 mL/4 mL) was added at room temperature boric acid ester B1 (71 mg,0.15 mmol), tetrakis (triphenylphosphine) palladium (24 mg,0.02 mmol) and sodium carbonate powder (Na 2 CO 3 ) (56 mg,0.53 mmol) and the reaction mixture was stirred overnight at 100deg.C under argon. LC-MS detection reaction was complete. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by a silica gel column (eluent: dichloromethane/methanol=10:1) to obtain a yellow solid product (83 mg). LC-MS m/z 946.2[ M+H ]] + 。
Fourth step: to the intermediate (80 mg,0.08 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (2 mL) at room temperature. The reaction mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the concentrated crude product was dissolved in tetrahydrofuran (5 mL), to which was added cesium fluoride (90 mg,0.6 mmol). The reaction mixture was stirred for a further 3 hours. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by HPLC to give a yellow solid, example 1 compound (13 mg). LC-MS [ M+H ] ] + :m/z 692.5。 1 HNMR(400MHz,DMSO)δ10.26(s,1H),7.95(m,1H),7.77(s,1H),7.45(m,1H),7.36(s,1H),7.05(s,1H),4.25(m,4H),3.92(s,1H),3.50(m,4H),2.99-2.81(m,2H),2.62(m,2H),2.48-2.39(m,2H),1.86-1.61(m,8H),1.37(m,3H),0.64(m,2H),0.41(m,2H).
The following example compounds were obtained in analogy to example 1 using the general preparation of examples using intermediates A1, B1, C2-C5 and other starting materials commercially available:
/>
example 6:1- ((1- (((4- (3, 8-diazabicyclo [3.2.1] oct-3-yl) -7- (8-ethyne-7-fluoro-3-hydroxynaphthalen-1-yl) -8-fluoropyrido [4,3-d ] pyrimidin-2-) oxy) methyl) cyclopropyl) methyl) -4-methyl-1, 4-azaphospha-hex-ne-4-oxide
The first step: the first step of the synthetic method of reference example 1 was performed using intermediate A2 (251 mg,1.0 mmol) and 3, 8-diazabicyclo [3.2.1]Tert-butyl octane-8-carboxylate (213 mg,1.0 mmol) was substituted to give the product as a yellow solid (305 mg). LC-MS [ M+H ]] + :m/z 428.1。
And a second step of: in the second step of the synthesis method of reference example 1, the above intermediate (305 mg,0.7 mmol) and intermediate C1 (155 mg,0.7 mmol) were subjected to substitution reaction to give a white solid compound (220 mg). LC-MS [ M+H ]] + :m/z 610.2。
And a third step of: in the third step of the synthetic method of reference example 1, substitution reaction was carried out with the above intermediate (245 mg,0.4 mmol) and boric acid ester intermediate C1 (210 mg,0.4 mmol) to give a white solid compound (110 mg). LC-MS [ M+H ]] + :m/z 912.2。
Fourth step: in the fourth step of the synthesis of reference example 1, the intermediate (110 mg,0.4 mmol) was deprotected with trifluoroacetic acid and ammonium fluoride to give after HPLC preparation the compound of example 6 (27 mg) as a white solid LC-MS [ M+H ] + :m/z 659.1。 1 H NMR(400MHz,DMSO)δ10.15(s,1H),9.03(s,1H),7.97(m,1H),7.46(m,1H),7.39(m,1H),7.18(m,1H),4.49(m,1H),4.34-4.23(m,3H),3.96(s,1H),3.64(m,1H),3.55(m,3H),2.93(m,2H),2.69-2.52(m,3H),2.47-2.37(m,2H),1.75(m,4H),1.67(m,4H),1.38(m,3H),0.65(m,2H),0.43(m,2H).
Using the general preparation of the examples, starting from intermediates A2, B1, C2-C5 and other starting materials commercially available, the following example compounds were obtained with reference to example 6 in a similar manner:
using the general preparation of the examples, with intermediates A1-A2, B1-B3, C1-C5 and other starting materials commercially available, the following example compounds were obtained in analogy to examples 1 and 2:
/>
/>
/>
example 31:1- ((1- (4- (3, 8-diazabicyclo [3.2.1] oct-3-yl) -7- (8-ethyl-7-fluoro-3-hydroxynaphthalene-1-)
Phenyl) -5,6,7, 8-tetrahydropyrido [3,4-d ] pyrimidin-2-yl) oxy) methyl) cyclopropyl) -4-methyl-1, 4-azaphospha-hex-4-oxide
The first step: to a methanol solution (20 mL) of boric acid ester B2 (500 mg,1.39 mmol) was added 30% hydrogen peroxide (20 mL) under ice-bath cooling. The reaction mixture was stirred at room temperature for 3 hours. After 50mL of water was added to the reaction mixture, ethyl acetate (30 mL) was extracted twice, and the combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was dissolved in methylene chloride (30 mL) and cooled in an ice bath to give a reaction solutionTo this mixture were added trifluoromethanesulfonic anhydride (290 mg,1.03 mmol) and triethylamine (0.5 mL). After the reaction mixture was stirred at room temperature for 2 hours, it was washed twice with saturated brine (20 mL), and the separated organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give a crude intermediate naphthol triflate (270 mg). LC-MS m/z 383.0[ M+H ] ] + .
And a second step of: under the protection of nitrogen, 7-benzyl-2, 4-dichloro-5, 6,7, 8-tetrahydropyrido [3,4-d ]]Pyrimidine (2.0 g,6.8 mmol) was dissolved in N, N-dimethylformamide DMF (20 mL) and 3, 8-diazabicyclo [3.2.1 ] was added]Tert-butyl octane-8-carboxylate (2.4 g,6.8 mmol) and N, N-diisopropylethylamine (2.6 g,20.4 mmol) were stirred overnight at room temperature. The LC-MS detection reaction was substantially complete, water (30 mL) was added to the reaction solution, and extraction was performed twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1) to give intermediate product (3.5 g) as a white solid. LC-MS [ M+H ]] + :m/z 470.2。
And a third step of: the above intermediate compound (1.0 g,2.1 mmol) and intermediate C1 (934 mg,4.3 mmol) were dissolved in toluene (30 mL) under nitrogen, cesium carbonate (2.08 g,9.6 mmol) and Pd were added 2 (dba) 3 (195 mg,0.21 mmol) and Ruphos (199mg, 0.43 mmol). The reaction was heated to 110℃and stirred overnight. The LC-MS detection reaction was substantially complete, water (30 mL) was added to the reaction solution, and extraction was performed twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: methanol/dichloromethane=1:20) to give an intermediate product (650 mg) as a yellow solid. LC-MS [ M+H ] ] + :m/z 651.4。
And a third step of: to t-butanol (15 mL) of the above intermediate compound (200 mg,0.31 mmol) was added wet palladium on carbon (30 mg) under a hydrogen atmosphere. The reaction was stirred at room temperature for 48 hours. The LC-MS detection reaction is basically complete, and the reaction solution is filtered through kieselguhr and washed by ethanol. The filtrate was concentrated under reduced pressure to give an intermediate product (170 mg) as a pale yellow solid. LC-MS [ M+H ]] + :m/z 561.3。
Fourth step: under the protection of nitrogenNext, the above intermediate compound (170 mg,0.3 mmol) and trifluoromethanesulfonic acid ester (120 mg,0.35 mmol) of the intermediate naphthol prepared above were dissolved in toluene (30 mL), cesium carbonate (163 mg,0.5 mmol) and Pd were added 2 (dba) 3 (34 mg,0.04 mmol) and 2-dicyclohexylphosphine-2 ',6' -diisopropyloxybiphenyl Ruphos (23 mg,0.05 mmol). The reaction was heated to 80℃and stirred overnight. The LC-MS detection reaction was substantially complete, water (30 mL) was added to the reaction solution, and extraction was performed twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained crude product was purified by HPLC to give a pale yellow solid intermediate product (40 mg). LC-MS [ M+H ]] + :m/z 749.4。
Fifth step: the intermediate compound (40 mg,0.05 mmol) was dissolved in tetrahydrofuran (10 mL) under nitrogen, and trifluoroacetic acid (1 mL) was added. Stirring for 30 minutes at room temperature. The LC-MS detection reaction was substantially complete, and to the reaction mixture was added saturated aqueous sodium bicarbonate (10 mL) and extracted twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained crude product was purified by HPLC to give the compound of example 31 (7 mg) as a pale yellow solid. LC-MS [ M+H ] ] + :m/z 649.3。 1 H NMR(400MHz,CD 3 OD)δ8.01(m,1H),7.58-7.25(m,3H),4.82-4.37(m,6H),3.88-3.65(m,7H),2.47-1.42(m,18H),1.08(m,3H),0.65-0.55(m,2H),0.46-0.36(m,2H)。
Using the general preparation of the examples, starting with intermediates C1-C5 and other starting materials commercially available, the following example compounds were obtained in analogy to example 31:
/>
/>
the following example compounds were obtained by analogy with reference to examples 1 and 6 using the general preparation of the examples using intermediates A1, A2, B1-B3, C1-C9 and other starting materials commercially available:
/>
/>
/>
example 71:1- ((1- (((7- (6-amino-4-methyl-3- (trifluoromethyl) pyridin-2-yl) -4- (3, 8-diazabicyclo [3.2.1] oct-3-yl) -6-chloro-8-fluoroquinazolin-2-yl) oxy) methyl) cyclopropyl) methyl) -4-methyl-1, 4-azaphospha-hex-4-oxide
The first step: to 3- (7-bromo-2, 6-dichloro-8-fluoroquinazolin-4-yl) -3, 8-diazabicyclo [3.2.1 under nitrogen protection]To a solution of tert-butyl octane-8-carboxylate (2.6 g,5.16 mmol) in N, N-dimethylformamide (30 mL) was added potassium fluoride (8.5 g,114 mmol). The reaction mixture was heated to 120 degrees and reacted overnight. After completion of the LC-MS detection reaction, water (60 mL) was added. The reaction mixture was extracted twice with ethyl acetate (100 mL), and the separated organic phase was dried over anhydrous sulfuric acid and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1) to give intermediate compound (900 mg) as a white solid. LC-MS m/z 491.0[ M+H ] ] + .
And a second step of: to a solution of the above intermediate compound (500 mg,1.02 mmol) and N, N-bis (4-methoxybenzyl) -4-methyl-6- (tri-N-butyltin) pyridin-2-amine (650 mg,1.02 mmol) in 1, 4-dioxane (20 mL) under nitrogen was added tetrakis (triphenylphosphine) palladium (173 mg,0.15 mmol), cuprous iodide (57 mg,0.3 mmol) and lithium chloride (65 mg,1.5 mmol). The reaction mixture was heated to 120℃and reacted overnight. LC-MS detection reaction was complete. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=2:1) to give a white solid compound (430 mg). LC-MS m/z 757.3[ M+H ]] + .
And a third step of: to a solution of the intermediate compound (430 mg,0.57 mmol) in N, N-dimethylformamide (10 mL) was added N-iodosuccinimide (129 mg,0.57 mmol). The reaction mixture was stirred at room temperature for 2 hours. The LC-MS detection reaction was essentially complete. After 50mL of water was added to the reaction mixture, the mixture was extracted twice with ethyl acetate (50 mL). The combined organic phases were concentrated under reduced pressure and the resulting crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=3:1) to give the compound as a white solid (510 mg). LC-MS m/z 883.2[ M+H ]] + .
Fourth step: to a solution of the intermediate compound (510 mg,0.58 mmol) in N, N-dimethylformamide (10 mL) under nitrogen was added cuprous iodide (385 mg,2.02 mmol), hexamethylphosphoric triamide (1.20 g,6.7 mmol) and fluorosulfonyl difluoromethyl acetate (1.29 g,6.7 mmol). The reaction mixture was heated to 90 degrees and stirred for 3 hours. After completion of the LC-MS detection reaction, 50mL of water was added to the reaction solution, followed by extraction twice with ethyl acetate (50 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to give a white solid compound (220 mg). LC-MS m/z 825.2[ M+H ] ] + .
Fifth step: the second-step method of reference example 1, the above intermediate compound (110 mg,0.13 mmol) was reacted with intermediate C1 to give a white solid intermediate compound (90 mg). LC-MS m/z 1022.4[ M+H ]] + .
Sixth step: at room temperature, in the aboveTo intermediate (90 mg,0.08 mmol) in dichloromethane (20 mL) was added trifluoroacetic acid (10 mL). The reaction mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the concentrated crude product was prepared by HPLC to give a white solid, the compound of example 71 (20 mg). LC-MS m/z 682.2[ M+H ]] + . 1 H NMR(400MHz,DMSO)δ7.87(m,1H),6.83(s,2H),6.50(s,1H),4.63-4.32(m,2H),4.27-4.17(m,4H),4.01-3.62(m,3H),3.56-3.37(m,1H),3.17-3.25(m,2H),2.91(m,1H),2.43(m,1H),2.37(s,3H),2.28-2.14(m,2H),2.07-1.51(m,8H),1.38(m,1H),0.92(m,1H),0.77-0.65(m,2H),0.38(m,1H).
Using the general preparation of the examples, starting from intermediates C7-C9 and other commercially available starting materials, the following example compounds were obtained in analogy to example 71:
example 76:6- (3-chloro-1-fluoro-13- ((1- (selenomorphine methyl) cyclopropyl) methoxy) -5a,6,7,8,9, 10-hexahydro-5H-6, 9-methano-azepino [2',1':3,4] [1,4] oxazepino [5,6,7-de ] quinazolin-2-yl) -4-methyl-5- (trifluoromethyl) pyridin-2-amine
Step one: sodium hydrogen (60% in mineral oil, 595mg,4.12 mmol) was added to a solution of A5 (1.2 g,4.95 mmol) in tetrahydrofuran (50 mL) at room temperature. After the mixture was stirred at room temperature for 30 minutes, a solution of compound A3 (1.36 g, mmol) in tetrahydrofuran (5 mL) was added. After the reaction mixture was heated to 60 degrees, the reaction was continued for 3 hours. After cooling to room temperature, the reaction mixture was quenched by addition of saturated aqueous ammonium chloride (30 mL) and concentrated under reduced pressure to remove most of the organic solvent. To the residue were added ethyl acetate (50 mL) and water (20 mL). The separated aqueous phase was extracted twice with ethyl acetate. The combined organic phases were concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=1:1) to give the compound as a yellow solid (1.02 g). LC-MS m/z:553.0[M+H] + 。
Step two: to a solution of the above intermediate compound (1.02 g,1.85 mmol) in methylene chloride (30 mL) were added BOP-Cl (1.41 g,5.55 mmol) and diisopropylethylamine (2.39 g,18.5 mmol). The reaction mixture was stirred at room temperature for 4 hours. LC-MS detection of the completion of the basic reaction, concentration of the reaction solution under reduced pressure, and purification of the crude product by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=2:1) gave a yellow solid compound (0.75 g). LC-MS m/z 535.0[ M+H ]] + 。
Step three: the first-step synthesis of reference example 71 was carried out by reacting the above intermediate compound (750 mg,1.40 mmol) with potassium fluoride to obtain a yellow solid compound (540 mg). LC-MS m/z 519.0[ M+H ]] + 。
Step four: the second-step synthesis of reference example 71 was performed using the above intermediate (540 mg,1.04 mmol) and N, N-bis (4-methoxybenzyl) -4-methyl-6- (tri-N-butyltin) pyridin-2-amine to give a yellow solid (439 mg). LC-MS m/z 785.3[ M+H ]] + 。
Step five: the third step of the synthesis method of reference example 71 was carried out using the above intermediate (439 mg,0.56 mmol) and iodosuccinimide to give a yellow solid compound (485 mg). LC-MS m/z 911.1[ M+H ]] + 。
Step six: the fourth synthesis step of reference example 71 was carried out using the above intermediate (481mg, 0.53 mmol) and methyl fluorosulfonyldifluoroacetate to give the compound (143 mg) as a yellow solid. LC-MS m/z 853.2[ M+H ] ] + 。
Step seven: the fifth step of the synthesis method of reference example 71 was carried out using the above intermediate (70 mg,0.08 mmol) and C6 to give the compound (45 mg) as a yellow solid. LC-MS m/z 1068.3[ M+H ]] + 。
Step eight: the sixth synthesis step, reference example 71, was carried out using the above intermediate (45 mg,0.04 mmol) and trifluoroacetic acid to give the compound (17 mg) as a yellow solid. LC-MS m/z 728.1[ M+H ]] + 。 1 H NMR(400MHz,CD 3 OD)δ7.93(s,1H),4.82-4.05(m,4H),3.84-3.45(m,6H),2.89-1.65(m,16H),0.65-0.53(m,2H),0.46-0.35(m,2H).
Using the general preparation of the examples, with intermediate C1 or C7-C9 and other starting materials commercially available, the following example compounds were obtained in analogy to example 76:
example 81: 3-chloro-5- (3-chloro-1-fluoro-13- ((1- (selenomorphine) methyl) cyclopropyl) methoxy) -5a,6,7,8,9, 10-hexahydro-5H-6, 9-methano-azepino [2',1':3,4] [1,4] oxazepino [5,6,7-de ] quinazolin-2-yl) -4- (trifluoromethyl) aniline
Step one: reference example 1, the third reaction step, 2-bromo-3-chloro-1, 13-difluoro-5 a,6,7,8,9, 10-hexahydro-5H-6, 9-bridge iminoazepino [2',1':3,4][1,4]Oxazepino [5,6,7-de ]]Quinazoline-15-formyl tert-butyl ester (250 mg,0.48 mmol) was reacted with (3-chloro-5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -4- (trifluoromethyl) -phenyl) carbamoyl tert-butyl ester to give the compound (150 mg) as a white solid. LC-MS m/z 732.1[ M+H ] ] + 。
Step two: reference example 71A fifth step synthesis was performed using the above intermediate compound (75 mg,0.10 mmol) and intermediate C6 to give a yellow solid compound (43 mg). LC-MS m/z 947.2[ M+H ]] + 。
Step three: referring to the sixth synthesis of example 71, the intermediate compound (42 mg,0.04 mmol) described above was reacted with trifluoroacetic acid to give the compound of example 81 (16 mg) as a yellow solid. LC-MS m/z 747.1[ M+H ]] + 。 1 H NMR(400MHz,CD 3 OD)δ6.96(s,1H),6.75(s,1H),4.82-4.05(m,4H),3.84-3.45(m,6H),2.49-1.65(m,13H),0.65-0.53(m,2H),0.46-0.35(m,2H).
Example 82: 3-chloro-5- (3-chloro-1-fluoro-13- ((1- ((4, 4-dimethyl-1, 4-azepin-1-yl) methyl) cyclopropyl) methoxy) -5a,6,7,8,9, 10-hexahydro-5H-6, 9-diimine azepino [2',1':3,4] [1,4] oxazepino [5,6,7-de ] quinazolin-2-yl) -4- (trifluoromethyl) aniline
Referring to the synthesis of example 81, the compound of example 82 was prepared as a white solid using intermediate C8 instead of C6. LC-MS m/z 725.2[ M+H ]] + . 1 H NMR(400MHz,CD 3 OD)δ6.96(s,1H),6.75(s,1H),4.82-4.05(m,4H),3.84-3.45(m,4H),2.49-1.65(m,13H),0.65-0.25(m,6H),0.01(s,6H).
Example 83:6- (4- (3, 8-diazabicyclo [3.2.1] oct-3-yl) -8-fluoro-2- ((1- (selenomorphine methyl) cyclopropyl) methoxy) pyrido [4,3-d ] pyrimidin-7-yl) -4-methyl-5- (trifluoromethyl) pyridin-2-amine
Step one: the second step of the Synthesis of reference example 6 was performed with intermediate 3- (2, 7-dichloro-8-fluoropyrido [4, 3-d)]Pyrimidin-4-yl) -3, 8-diazabicyclo [3.2.1 ]Reaction of octane-8-formyl tert-butyl ester (262 mg,0.61 mmol) with intermediate C6 gave the compound (280 mg) as a white solid. LC-MS m/z 627.1[ M+H ]] + .
Step two: the second reaction step of reference example 71 was carried out using the above intermediate compound (280 mg,0.45 mmol) and N, N-bis (4-methoxybenzyl) -4-methyl-6- (tri-N-butyltin) pyridin-2-amine to give a yellow solid compound (204 mg). LC-MS m/z 939.3[ M+H ]] + .
Step three: the third reaction step of reference example 71 was carried out using the above intermediate compound (204 mg,0.22 mmol) and N-iodosuccinimide to give a yellow solid compound (160 mg). LC-MS m/z 1065.2[ M+H ]] + .
Step four: the fourth step of the Synthesis method of reference example 71 was repeated with 160mg (0.15 mmol) of the intermediate compound and fluorosulfonyl group as mentioned aboveMethyl difluoroacetate was reacted to prepare a yellow solid compound (55 mg). LC-MS m/z 1007.0[ M+H ]] + .
Step five: referring to the sixth synthesis of example 71, the intermediate compound (55 mg,0.05 mmol) described above was reacted with trifluoroacetic acid to give the compound of example 83 (22 mg) as a yellow solid. LC-MS m/z 667.0[ M+H ]] + . 1 H NMR(400MHz,DMSO)δ9.00(s,1H),6.79(s,2H),6.49(s,1H),4.37(m,2H),4.26(m,2H),3.56(m,4H),2.84-2.76(m,4H),2.61-2.36(m,6H),2.36(s,3H),1.62(m,4H),0.64(t,J=4.9Hz,2H),0.41(t,J=4.9Hz,2H).
Referring to the preparation of example 83, the following examples 84 and 85 were prepared using the general preparation of examples using different borates and intermediates C8 or C9 and other starting materials commercially available:
Example 86:6- (1-fluoro-12- ((1- (selenomorphine methyl) cyclopropyl) methoxy) -5a,6,7,8,9, 10-hexahydro-5H-4-epoxy-3, 10a,11,13, 14-pentaaza-6, 9-menaquino [1,8-ab ] hept-2-yl) -4-methyl-5- (trifluoromethyl) pyridin-2-amine
Step one: to a solution of A5 (500 mg,2.06 mmol) in methylene chloride (50 mL) was added imidazole (500 mg,7.3 mmol) and tert-butyldiphenylchlorosilane (2.33 g,8.5 mmol). The reaction mixture was stirred at room temperature overnight. To the reaction solution was added a saturated ammonium chloride solution (20 mL). The separated organic phase was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to give a white solid compound (780 mg). LC-MS m/z 481.2[ M+H ]] + .
Step two: to a solution of intermediate A4 (433 mg,1.51 mmol) in dichloromethane (50 mL) were added the above intermediate (780 mg,1.62 mmol) and N, N-diisopropylethylamine (387 mg,3.0 mmol). The reaction mixture was stirred at room temperature for 20 hours. After the reaction solution was washed with water, the organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3:1) to give a yellow solid compound (590 mg). LC-MS m/z 730.1[ M+H ]] + .
Step three: referring to the synthesis of example 1, the second step, intermediate compound (390 mg,0.53 mmol) described above was reacted with intermediate C6 to give yellow solid compound (450 mg). LC-MS m/z 929.2[ M+H ] ] + .
Step four: to a solution of the above intermediate compound (450 mg,0.48 mmol) in tetrahydrofuran was added a solution of tetrabutylammonium fluoride in tetrahydrofuran (1M, 1.5mL,1.5 mmol). The reaction mixture was stirred at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=2:1) to obtain a yellow solid compound (235 mg). LC-MS m/z 655.1[ M+H ]] + .
Step five: the second-step synthesis of reference example 71 was performed using the above intermediate (235 mg,0.36 mmol) and N, N-bis (4-methoxybenzyl) -4-methyl-6- (tri-N-butyltin) pyridin-2-amine to give a yellow solid compound (105 mg). LC-MS m/z 967.3[ M+H ]] + .
Step six: the third step of the synthesis method of reference example 71 was carried out using the above intermediate (105 mg,0.11 mmol) and iodosuccinimide to give a yellow solid compound (89 mg). LC-MS m/z 1093.2[ M+H ]] + .
Step seven: the fourth synthesis step of reference example 71 was carried out using the above intermediate (89 mg,0.08 mmol) and methyl fluorosulfonyl difluoroacetate to give the compound (35 mg) as a yellow solid. LC-MS m/z 1035.3[ M+H ]] + .
Step eight: the sixth synthesis step, referenced in example 71, was carried out using the above intermediate (35 mg,0.03 mmol) in reaction with trifluoroacetic acid to provide the compound of example 86 (9 mg) as a yellow solid. LC-MS m/z 695.1 [M+H] + . 1 H NMR(400MHz,CD 3 OD)δ7.95(s,1H),4.82-4.05(m,4H),3.84-3.45(m,6H),2.89-1.65(m,15H),0.65-0.53(m,2H),0.46-0.35(m,2H).
Referring to the preparation of example 86, the following examples were prepared using the general preparation of examples using different borates and intermediates C6-C9 and other starting materials commercially available:
referring to the preparation of example 71, the following examples were prepared using the general preparation of examples using different borates and intermediates C7-C9 and other starting materials commercially available:
/>
referring to the preparation of example 83, the following examples were prepared using the general preparation of examples using different borates and intermediates C7-C9 and other starting materials commercially available:
/>
/>
/>
/>
test example 1 pair KRAS of the inventive Compound G12D Impact test of mediated ERK phosphorylation Capacity
The testing method comprises the following steps: 1) Expression of KRAS G12D AGS cells (ATCC) were cultured in DMEM medium containing 10% fetal bovine serum, 10mM HEPES and penicillin/streptomycin, inoculated in 96-well plates at a density of 40,000 cells/well, and attached for 12-14 hours. 2) After 3 hours, the medium was removed, 150. Mu.L of 4.0% formaldehyde was added, and the plate was incubated at room temperature for 20 minutes. 3) The plates were washed with PBS and infiltrated with 150. Mu.L ice-cold methanol for 10 min. 4) Binding of non-specific antibodies to the plates was blocked with 100 μl of blocking buffer for 1 hour at room temperature. Phosphorylation of ERK was detected using p-ERK specific antibodies, GAPDH as an internal standard. The information and experimental conditions of the antibody are as follows: p-ERK (Cell signaling) was diluted 1:500 in blocking buffer+0.05% tween 20; GAPDH was diluted 1:500 in blocking buffer+0.05% tween 20. The antibody was incubated for 2h at room temperature, PBS+0.05% Tween20, and the plate was washed. The secondary antibodies used to display primary antibodies were added as follows: anti-rabbit-680 was diluted 1:1000 in blocking buffer+0.05% tween20, anti-mouse-800 was diluted 1:1000 in blocking buffer+0.05% tween20 and incubated for 1 hour at room temperature. 5) Plates were washed with PBS +0.05% tween20, 100 μl PBS was added to each well and the plates were read. 6) The phosphorylated ERK (Thr 202/Tyr 204) signal was normalized to GAPDH signal for each well and the percentage of DMSO control value was calculated. Calculation of IC by four-parameter dose-response curve fitting 50 Values.
Results: the invention provides a significant portion of the compounds of the examples which have a significant inhibitory effect on phosphorylated ERK levels in AGS cells, IC of all examples 50 All less than 3000nM, and some examples even less than 100nM. Specific activity results are shown in the table. (C represents 1000 nM.ltoreq.IC 50 <3000nM, B represents 500 nM.ltoreq.IC 50 <1000nM, A represents IC 50 <500nM)
/>
/>
Test example two, test example Compounds for BaF3-KRAS-G12D cell proliferation inhibition Activity
The test adopts CellTiter-Glo (CTG) kit provided by Promega company, which is a method for detecting cell viability by a homogenization method, and the cell viability of the cultured cells is determined by quantifying ATP.
1. Experimental reagent consumable: RPMI1640 (Hyclone, SH 30809.01), fetal Bovine Serum (FBS, gibco, 10099-141), phosphate Buffered Saline (PBS, solarbio, P1020-500), celltiter Glo assay kit (Promega, G7573), blank 96-cell culture plate (Thermo, 165305).
2. Experimental instrument equipment: CO2 incubator (Thermo Scientific, model 3100 Series), microscope (OLYMPUS, CKX41 SF), multifunctional microplate reader (BMG,plus), biosafety cabinet (Thermo, model 1300 Series A2).
3. Cell proliferation assay: all cell lines were cultured in complete medium at 37℃under 5% CO 2. Cells in the logarithmic growth phase were harvested and counted using a platelet counter. Cell viability was checked by trypan blue exclusion, ensuring that cell viability was above 90%. The cell density was adjusted using complete medium and then seeded into 96 well cell culture plates with 90 μl total of 3000 cells per well. Cells in 96-well plates were incubated at 37℃under 5% CO 2. A 10-fold drug solution was prepared and then transferred from 10 μl of each serial diluted compound to the corresponding experimental well of a 96-well cell plate, the initial concentration of compound test 10um, 3-fold dilution, 9 concentrations, three multiplex wells were set for each drug concentration. Cells in the dosed 96-well plates were incubated at 37℃under 5% CO2 for a further 72 hours before CTG analysis. The CTG reagent was thawed and the cell plates equilibrated to room temperature for 30 minutes. An equal volume of CTG solution was added to each well. Cells were lysed by shaking on an orbital shaker for 5 minutes. The cell plates were left at room temperature for 20 minutes to stabilize the luminescence signal. Using Luminescence Read Mode, luminescence values (luminescences) were read and data collected.
4. Data analysis: the data were analyzed using GraphPad Prism 7.0 software, and non-linear S-curve regression was used to fit the data to yield the dose-response curve, and IC50 values were calculated therefrom. Cell viability (%) = (Lum) Drug to be tested -Lum Culture broth control )/(Lum Cell control -Lum Culture broth control ) X 100%. (A represents IC 50 Value of<200nM, B represents 200 nM.ltoreq.IC 50 Value of<1000nM, C represents IC 50 ≥1000nM)
/>
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Claims (9)
1. A nitrogen-containing heterocyclic compound represented by the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, stereoisomer, solvate, polymorph or prodrug thereof,
wherein,
R 1 selected from substituted or unsubstituted 3-12 membered cycloalkyl or heterocycloalkyl, said substituents being selected from one or more R 10 ,R 10 Independently selected from: deuterium, halogen, cyano, hydroxy, amino, C1-C6 acyl, sulfonyl, - (CO) -NR 11 R 12 、C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylcyano, C 1 -C 6 Alkyl hydroxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered aryl or heteroaryl, or two R 10 And together with the carbon atom or heteroatom to which they are attached form a 3-12 membered saturated or partially unsaturated or aromatic carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings; r is R 11 、R 12 Independently selected from hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, 3-8 membered cycloalkyl or heterocycloalkyl, or R 11 、R 12 Together with the attached N atom form a 3-8 membered cycloalkyl or heterocycloalkyl group; the heterocyclic alkyl, heteroaryl and heterocyclic ring system contains 1-3 hetero atoms selected from N, O, S, P;
R 2 selected from substituted or unsubstituted C 1 -C 6 Alkyl, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-12 membered aryl or heteroaryl, C 1 -C 6 An alkyl-substituted 3-12 membered cycloalkyl or heterocycloalkyl, a 5-16 membered saturated or partially unsaturated carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings; the substituents are one or more R 21 ,R 21 Independently selected from the following groups: halogen, cyano, hydroxy, amino, (C) 1 -C 6 Alkyl) NH- (C 1 -C 6 Alkyl group 2 N-、(C 1 -C 6 Alkyl) NH-C 1 -C 6 Alkyl-, (C) 1 -C 6 Alkyl group 2 N-C 1 -C 6 Alkyl-, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-12 membered aryl or heteroaryl, 3-12 membered cycloalkyl or heterocycloalkyl substituted C 1 -C 6 Alkyl, etc., or two R 21 Together with the carbon atom or heteroatom to which they are attached, form a 3-8 membered cycloalkyl or heterocycloalkyl group; the 3-12 membered heterocycloalkyl, 5-12 membered heteroaryl, 3-12 membered heterocycloalkyl substituted C 1 -C 6 The heterocycloalkyl, 5-16 membered saturated or partially unsaturated heterocyclic ring system, 5-12 membered heteroaryl or 3-8 membered heterocycloalkyl in the alkyl group contains 1 to 3 heteroatoms independently selected from N, O, S, P, si, B, se, which heteroatoms may optionally be in different oxidation states; r is R 21 May further optionally be substituted with one or more R 211 Substituted, R 211 Independently selected from halogen, cyano, hydroxy, amino, C 1 -C 6 Alkyl-imino-, cyano-imino-, 3-6 membered cycloalkyl-imino-, C 1 -C 6 Alkyl, C of (2) 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, 3-to 10-membered cycloalkyl or heterocycloalkyl, 3-to 10-membered halocycloalkyl or haloheterocycloalkyl substitution; r is R 211 Wherein said heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O, S, P, si, se;
l is selected from carbon-carbon single bond, carbon-carbon double bond, carbon-carbon triple bond, CHR 5 、O、S(O) t Or NR (NR) 5a R 5b ;R 5 、R 5a And R is 5b Selected from H or C 1 -C 6 Alkyl of (a);
L 1 selected from direct bond, CHR 5 、O、S(O) t 、NR 5a R 5b ;R 5 、R 5a And R is 5b Selected from H, C 1 -C 6 Alkyl of (a);
R 4 is one or more groups independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkoxy, 3-to 12-membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, -P (O) t- (C) 1 -C 6 Alkyl), -S (O) t- (C) 1 -C 6 Alkyl), an amide group, a sulfonamide group, a urea group, a 5-to 12-membered aryl or heteroaryl group, or R as defined above 1 And R is 4 Any two substituents between the two groups form a 3-12 membered saturated or partially unsaturated or aromatic ring system or aromatic heterocyclic system through carbon atoms or hetero atoms; the heterocycloalkyl, heteroaryl and aromatic heterocyclic system contains 1-3 hetero atoms selected from N, O, S, P;
t is selected from 0-2;
ar is selected from a substituted or unsubstituted 5-12 membered aromatic or heteroaromatic ring, and may be substituted with one or more R 3 Substitution; r is R 3 Independently selected from halogen, hydroxy, amino, cyano, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, (C) 1 -C 6 Alkyl) NH- (C 1 -C 6 Alkyl group 2 N-; the heterocycloalkyl group and the aromatic heterocycle contain 1 to 3 hetero atoms selected from N, O, S, P;
M is N or CR 6 ;R 6 Selected from hydrogen, deuterium, halogen, -CN, C 1 -C 3 Alkyl, C 1 -C 3 A haloalkyl group; the method comprises the steps of carrying out a first treatment on the surface of the
Cy is selected from a 5-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring system, or a 5-6 membered aromatic or heteroaromatic ring system; the heterocyclic ring system, the aromatic heterocycle or the aromatic heterocycle system contains 1-3 hetero atoms selected from N, O, S, P.
2. The nitrogen-containing heterocyclic compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, according to claim 1, which has a structure represented by the formula (II):
wherein W, W 1 Each independently selected from N or CR 4 ;
Ar、R 3 、R 4 、M、L、L 1 、R 10 、R 2 、R 1 The range of (2) is as defined in claim 1.
3. A nitrogen-containing heterocyclic compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, as claimed in claim 1, wherein one or more of the following conditions are satisfied:
(1)C 2 -C 6 alkenyl group is C 2 -C 4 Alkenyl, preferably ethenyl or propenyl;
(2)C 2 -C 6 alkynyl is C 2 -C 4 Alkynyl, preferably
(3)C 1 -C 6 Alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, primary butyl, secondary butyl or tertiary butyl;
(4)C 1 -C 6 Halogen in the haloalkyl is fluorine, chlorine, bromine or iodine;
(5) The 3-6 membered cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexenyl or cyclohexyl.
4. A nitrogen-containing heterocyclic compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, as claimed in claim 1, wherein:
m is N, C-H, C-F, C-CN;
alternatively, cy is selected from the group consisting of:
alternatively, R 4 Preferably selected from hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl groups of (a) and the like;
alternatively, R 1 Selected from a substituted or unsubstituted 5-10 membered cycloalkyl or heterocycloalkyl, preferably from a substituted or unsubstituted piperidine ring, piperazine ring, homopiperazine ring, pyrrolidine ring, homopiperidine ring, morpholine ring, homomorpholine ring; said substituent R 10 Preferably from halogen, C1-C6 alkyl, hydroxy, amino, =O, 3-to 6-membered saturated or partially unsaturated carbocyclic or heterocyclic ring systems, or two R 10 And together with the carbon atom or heteroatom to which they are attached form a 5-6 membered saturated or partially unsaturated or aromatic carbocyclic or heterocyclic ring system including spiro, bridged, fused or fused rings;
Alternatively, when R 1 And R is 4 The compounds of formula (I) may have the structure of formula (III) when a new heterocyclic ring system is constituted by sharing one carbon or heteroatom (nitrogen, or oxygen, or sulfur atom),
wherein r is 0, 1, 2 or 3; p is selected from 1 or 2; w, W 1 Independently selected from N or CR 4 ;
L 2 Is O, S or NR 7 ,R 7 Is hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl of (a); l (L) 2 Preferably O;
q is- (CH) 2 )n-L 3 -(CH 2 ) n-or absent; l (L) 3 Selected from O, S, NR 8 Or is absent, R 8 Is hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl of (a); q is preferably selected from-CH 2 CH 2 -;
R 10 Independently selected from deuterium, halogen, cyano, hydroxy, amino, C1-C6 acyl, sulfonyl, - (CO) -NR 11 R 12 、C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkylcyano, C 1 -C 6 Alkyl hydroxy, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-6 membered aryl or heteroaryl; other groups Ar, R 3 、R 4 、M、L、L 1 、R 2 As claimed in claim 1;
preferably +.>
Alternatively, ar is preferably selected from a benzene ring, a pyridine ring, a naphthalene ring, a benzothiazole ring, a benzothiophene ring, an indazole ring, an indole ring, an azaindole ring, a benzimidazole ring, etc.;
Alternatively, R 3 Independently selected from hydrogen, halogen, hydroxy, amino, cyano, and C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy groups, and the like;
alternatively, L is selected from: CH (CH) 2 O, NH or S;
alternatively, L 1 Selected from: direct bond, CH 2 O, NH or S;
alternatively, when R 21 In the case of 3-12 membered heterocycloalkyl, the 3-12 membered heterocycloalkyl is 5-10 membered heterocycloalkyl, preferably
Alternatively, two R 21 When taken together with the carbon atom or heteroatom to which they are attached, form a 3-8 membered cycloalkyl, said 3-8 membered cycloalkyl is cyclopropyl;
alternatively, when R 2 In the case of substituted C1-C6 alkyl, the substituted C1-C6 alkyl isWherein m and n are each an integer from 0 to 3; m and n are preferably 1 and 2; ry is selected from 3-12 membered cycloalkyl or heterocycloalkyl, 5-10 membered aryl, 5-10 membered heteroaryl, said heterocycloalkyl or heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, S, P, si, B, se, said heteroatoms optionally being in different oxidation states; r is R p And R is q Selected from hydrogen, halogen, C 1 -C 6 Alkyl or alkoxy, 3-6 membered cycloalkyl or heterocycloalkyl, hydroxy, amino, or R p And R is q Forming a 3-8 membered cycloalkyl or heterocycloalkyl; r is R p 、R q Ry or R p And R is q The 3-8 membered cycloalkyl or heterocycloalkyl formed may optionally be further substituted with one or more R 211 Substituted, R 211 Independently selected from halogen, cyano, C 1 -C 6 Alkyl-imino-, cyano-imino-, 3-6 membered cycloalkyl-imino-, C 1 -C 6 Alkyl or haloalkyl, 3-12 membered cycloalkyl or heterocycloalkyl, 3-12 membered halocycloalkyl or haloheterocycloalkyl.
5. The nitrogen-containing heterocyclic compound as described in claim 1, which is represented by the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof,
R 1 preferably selected from
Alternatively, cy is selected from
Alternatively, R 3 Ar is selected from a substituted or unsubstituted benzene ring, pyridine ring, naphthalene ring, benzothiazole ring, benzothiophene ring; the substituents are independently selected from hydroxy, amino, halogen, cyano, vinyl, ethynyl, C1-C3 alkyl or haloalkyl;
alternatively, L is preferably selected from-O-;
alternatively, L 1 Preferably from direct bond, CH 2 ;
Alternatively, R 2 In the case of substituted C1-C6 alkyl, the substituted C1-C6 alkyl isWherein Ry is selected from substituted 5-12 membered cycloalkyl or 5-12 membered heterocycloalkyl containing 1-3 heteroatoms selected from S, P, se or Si; r is R p And R is q Selected from hydrogen, halogen, C 1 -C 6 Alkyl or alkane of (2)Oxy, hydroxy, amino, or R p And R is q Forming a 3-8 membered cycloalkyl or heterocycloalkyl; r is R p 、R q Ry or R p And R is q The 3-8 membered cycloalkyl or heterocycloalkyl formed may optionally be further substituted with one or more R 211 Substituted, R 211 Independently selected from halogen, cyano, C 1 -C 6 Alkyl-imino-, cyano-imino-, 3-6 membered cycloalkyl-imino-, C 1 -C 6 An alkyl or haloalkyl group, a 3-12 membered cycloalkyl or heterocycloalkyl group, a 3-12 membered halocycloalkyl or haloheterocycloalkyl group;
alternatively, R 4 Selected from hydrogen, deuterium, halogen, C 1 -C 3 Alkyl, C 1 -C 3 Haloalkyl, cyano, amino, C 3 -C 6 Cycloalkyl or halocycloalkyl, C 2 -C 4 Alkenyl group, C 2 -C 4 Alkynyl groups of (a) and the like.
6. A nitrogen-containing heterocyclic compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, as claimed in claim 1, wherein:
m is preferably N, C-H, C-F, C-CN;
alternatively, cy is preferably selected from
Alternatively, R 1 Preferably selected from:
r is as described above 1 Any hydrogen of the radicals being able to be replaced by halogen, hydroxy, C 1 -C 6 Alkyl, or = O substitution;
alternatively, R 3 Ar is selected from
Alternatively, R 2 Preferably is R 6 Selected from hydrogen, deuterium, halogen, cyano, C 1 -C 3 Alkyl or C 1 -C 3 A haloalkyl group;
alternatively, R 4 Selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, trifluoromethyl, cyano, amino, cyclopropyl, vinyl, ethynyl, and the like;
alternatively, R 11 、R 12 Independently selected from hydrogen, halogen, methyl;
alternatively, when R 11 、R 12 When taken together with the attached N atom form a 3-8 membered heterocycloalkyl, the 3-8 membered heterocycloalkyl is preferably
Alternatively, R p And R is R q Forming a three-membered carbocyclic ring with the attached carbon atom;
alternatively, ry is preferably
Alternatively, when R 10 Is C 1 -C 6 When alkyl hydroxy of (C) 1 -C 6 Preferably HO-CH 2 -、HO-CH 2 -CH 2 -。
7. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, wherein the compound has the structure:
8. a pharmaceutical composition comprising an effective amount of the nitrogen-containing heterocyclic compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, and a pharmaceutically acceptable carrier.
9. Use of a nitrogen-containing heterocyclic compound as described in any one of claims 1-7, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, or a pharmaceutical composition as described in claim 8, for the preparation of a Ras mutein inhibitor or medicament; the Ras mutant protein can be KRAS G12D The method comprises the steps of carrying out a first treatment on the surface of the The medicine can be used for treating diseases related to activity or expression quantity of Ras mutant protein; alternatively, the drug may be a therapeutic drug for a tumor; the tumor is independently selected from non-small cell lung cancer, small cellLung cancer, lung adenocarcinoma, lung squamous carcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, stomach cancer, intestinal cancer, bile duct cancer, brain cancer, leukemia, lymphoma, fibroma, sarcoma, basal cell carcinoma, glioma, renal cancer, melanoma, bone cancer, thyroid cancer, nasopharyngeal cancer, pancreatic cancer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022112154753 | 2022-09-30 | ||
CN202211215475 | 2022-09-30 | ||
CN202211298271 | 2022-10-22 | ||
CN2022112982710 | 2022-10-22 | ||
CN202310206032 | 2023-03-06 | ||
CN2023102060326 | 2023-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117800976A true CN117800976A (en) | 2024-04-02 |
Family
ID=90427732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311267818.5A Pending CN117800976A (en) | 2022-09-30 | 2023-09-28 | Nitrogen-containing heterocyclic compound, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117800976A (en) |
-
2023
- 2023-09-28 CN CN202311267818.5A patent/CN117800976A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113563323B (en) | Benzothiazolyl biaryl compound, preparation method and application | |
JP7335882B2 (en) | Pyrimidine-condensed ring compound, method for producing the same, and use | |
EP3112364B1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
KR20220119088A (en) | KRAS mutant protein inhibitor | |
CN115448923B (en) | Pyrimidine-fused ring compound, preparation method and application thereof | |
CN112142735B (en) | Condensed cyanopyridine compound, preparation method and application | |
JP6457623B2 (en) | 2,4-disubstituted 7H-pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation and use in medicine | |
CN112552294B (en) | Piperazine heterocyclic derivative-containing inhibitor, preparation method and application thereof | |
CN113135910A (en) | Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and pharmaceutical application thereof | |
JP7384536B2 (en) | Quinazoline compounds and their preparation, use and pharmaceutical compositions | |
EP4194441A1 (en) | Nitroxoline derivative, preparation method therefor, and use thereof | |
CN113527299B (en) | Nitrogen-containing condensed ring compound, preparation method and application | |
KR20170035944A (en) | FUSED QUINOLINE COMPOUNDS AS PI3K, mTOR INHIBITORS | |
CN113387962A (en) | Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof | |
AU2019331934A1 (en) | Multi-substituted pyridone derivatives and medical use thereof | |
JP2022547777A (en) | Hydantoin derivative | |
CN117800976A (en) | Nitrogen-containing heterocyclic compound, preparation method and application | |
CN114394965A (en) | Triazolopyridine compound and preparation method and application thereof | |
CN116143805A (en) | Nitrogen-containing heterocyclic biaryl compounds, preparation method and application | |
CN116143806A (en) | Nitrogen-containing heterocyclic compound, preparation method and application | |
JP7449028B2 (en) | EGFR inhibitor and its manufacturing method and application | |
CN115960117B (en) | Sulfur-containing fused ring derivative inhibitor, preparation method and application thereof | |
CN113563341B (en) | Substituted pyrazolo [1,5-a ] pyrimidine compounds as Trk inhibitors | |
WO2023134582A1 (en) | Pyrimidine-2,4-diamine derivatives as well as preparation method therefor and use thereof | |
CN112384506B (en) | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |